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Abstract
Driving under the influence of drugs (DUID) cases represent the largest portion of cases
handled in most forensic toxicology laboratories. Blood is a commonly used specimen and is
often analyzed using gas chromatography-mass spectrometry (GC/MS). A common extraction
for this method requires two milliliters of blood. If more than one extraction is necessary, a
larger volume of blood is required. Recently, laboratories have started using liquid
chromatography-mass spectrometry (LC/MS) to obtain a lower limit of detection and
extractions which require less blood to complete. Currently, the Oklahoma State Bureau of
Investigation (OSBI) Laboratory operates LC-based extractions which require 250 to 500
microliters (µL) of sample to complete, but these are limited to specific drug classes. A general
drug screen for forty drugs has been developed and validated using 250 microliters of blood.
Even with this reduction of volume requirements, there are still instances in which less than
one milliliter (mL) of blood is available for use by the analyst. An additional validation has been
completed which required 100 microliters of sample to confirm the presence of thirty-nine
drugs. A comparison between these methods was completed to verify the sensitivity of the 100
microliter method.
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Introduction
Breath and blood are commonly encountered specimens associated with the
assessment of driving under the influence of alcohol or drugs, hereinafter referred to as DUI
cases, at this time. Urine is not a practical sample for DUI cases due to the fact that it does not
establish time of impairment.  Breath is only a viable specimen in the detection of volatile
compounds. This leaves blood as the only suitable option to confirm the presence or absence
of other intoxicating drugs. Limited sample can be a problem when it comes to obtaining
results for DUI cases. With extractions that may require up to two milliliters of blood to
perform, the completion of confirmatory testing could be prevented by lack of sample. Not to
be forgotten, there must be enough sample available for independent testing if it is requested
by the defendant. With all of these requirements, an extraction requiring significantly less
blood is something that would allow a larger number of limited-sample cases to be more
completely analyzed.
Literature Review
There are two types of instrumentation which are commonly used for drug confirmation
in the field of forensic toxicology. They are gas chromatography-mass spectrometry (GC/MS)
and liquid chromatography-mass spectrometry (LC/MS or LC/MS-MS). The main difference is
apparent in the names of the instruments. However, there are many similarities between the
two. The extracted sample is introduced into the instrument through the injector. It then
moves through the chromatographic column, which separates the components of a mixture.
After the components have traveled through the column, they pass through the mass
spectrometer. As they pass through this portion of the instrument, they are broken into
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reproducible fragments. The abundance of these fragments is then recorded by the detector,
which uses this information to produce a mass spectrum or “picture” of the fragments (see
Figure 1).  The time from injection to detection, known as the retention time, is recorded for
the fragments of the components. The retention time and mass spectrum can be used to
compare unknowns to knowns in a library if one is available (Agilent, 2007).
Figure 1. Cocaine spectrum.
A GC/MS uses a carrier gas to transport the injected mixture through the column and to
the detector, which necessitates that the sample be turned into a gas from a liquid. This
requires the analyte to be volatile or amenable to chemical derivatization to render the
compound volatile. The sample is introduced into the instrument and is taken from
atmospheric pressure to the system pressure, vaporized, and all or part of the resulting gas is
introduced into the column. Helium is often used as the carrier gas, which moves through the
instrument at a constant pressure and flow rate designated by the method being used. GC/MS
is appropriate for analytes that do not ionize well using LC/MS techniques. Electron ionization
(EI) is a commonly used ionization technique. EI is a very robust and reproducible technique
which does not suffer from ion suppression caused by a co-eluting compound (Agilent, 2007).
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In this technique, sample components collide with electrons emitted from a filament and are
ionized. The molecules are broken down at the same time creating fragments. Although EI is a
more common technique, there is another termed chemical ionization (CI). This technique
involves ionization of reagent gas molecules which usually produces ions of the analyte by
collision. Unlike EI, a preponderance of the ions created under the CI process result in the
ability to determine the molecular weight due to the fact that most remain intact and few
fragment ions are produced. GC/MS instruments also cost less than their LC/MS analogues.
A LC/MS can separate metabolites, products of the breakdown of drugs in the human
body that are not volatile or derivatized. This allows for a wider range of chemical species to be
analyzed. The commonly-used ionization techniques are electrospray ionization1 (ESI) and
atmospheric pressure chemical ionization2 (APCI). Both of these techniques allow for ionization
suppression which can cause co-eluting compounds to be underestimated or not detected at
all. However, LC/MS almost always produces a molecular ion that can be used to limit the
possible identities of a given analyte. Often, selected ion monitoring (SIM)3 or multiple reaction
monitoring (MRM)4 are used which allows for a lower limit of detection (LOD) or limit of
quantitation (LOQ) (Agilent, 2007).
In the last decade, the LC/MS has grown in popularity in forensic toxicology. With this
increased popularity, new methods are constantly being developed, often for specific drugs or
drug classes. In 2012, a method to detect twenty-five designer cathinones, part of the
1 High voltage is applied to a liquid to create an aerosol.
2 Utilizes gas-phase ion-molecule reactions at atmospheric pressure.
3 Ions in a certain mass-to-charge ratio range are scanned for and are detected by the instrument eliminating
unwanted ions.
4 Used to target compounds of interest and lower background noise by moving only the ions for the drugs of
interest through the instrument to the detector.
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amphetamine class, was developed by Ammann, Mclaren, Gerostamoulos, and Beyers. This
extraction requires one hundred microliters of blood, one milliliter of 1-chlorobutane
containing ten percent isopropanol, one hundred microliters of internal standard, and two
hundred microliters of trizma buffer (pH 9.2). The solvent layer is evaporated to dryness and
reconstituted with 500 microliters of a 95:5 mixture of 50 millimoles per liter (mmol/L) aqueous
ammonium formate and acetonitrile containing 0.1 percent formic acid. Ante-mortem blood
was used for verification and calibration standards. A signal-to-noise ratio of at least 10:1 for
the setting of all lower limits of quantitation (LLOQ) was also required. The researchers
followed internationally accepted recommendations5 and were successfully able to validate the
method for all twenty-five compounds.
Clarkson, Lacy, Flignrt, Thiersch, Howard, Harruff, and Logan (2004) collected data from
all death investigation and impaired driving cases which tested positive for tramadol between
1995 and 2000 at the Washington State Toxicology Laboratory. In total, there were 75 cases.
Copies of the records containing details surrounding individual deaths, death certificates, and
autopsy findings were also obtained for all death investigation cases. Cases were excluded if
any of this information was missing or if an autopsy was not completed. This left a total of 66
cases. 46 cases were found to be one of the following: a tramadol-caused death (n=4),
tramadol-contributed to cause of death (n=27), or an incidental appearance of tramadol (n=15).
In both 2007 and 2013-2014, the National Highway Traffic Safety Administration
(NHTSA) conducted national surveys to estimate the prevalence of alcohol consumption and/or
drug use and driving in the United States. In the 2007 study, only weekend nighttime drivers’
5 Guidelines provided by the US Department of Health and Human Services as well as multiple peer reviewed
recommendations.  These have been widely accepted in the toxicology community.
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data was collected. In the 2013-2014 survey, data collection included weekend nighttime and
weekday daytime drivers. It was revealed in both surveys that there was a significant decline in
alcohol-impaired driving since the initial NHTSA survey in 1973. However, noted was an
increase in drivers having taken illegal drugs as well as an increase in drivers taking lawful
medications, although some without the benefit of the associated prescription. The results of
blood tests showed an increase from 9.8 percent to 14.3 percent for drivers with illegal drugs in
their systems while driving. The increase was smaller for those with legal medications in their
systems, 4.0 percent to 4.9 percent. The illegal drug category includes all drivers with any
illegal drug in their system even if they had prescription and/or over-the-counter (OTC)
medications in their system as well. The incidents of the use of THC also rose between the
2007 and 2013-2014 surveys. In 2007, the incidents of THC were 7.6 percent and have
increased to 11.7 percent in the latest survey (Compton & Berning, 2009). Since there were
two time periods used in the 2013-2014 survey, weekday daytime drivers and weekend
nighttime drivers, NHTSA was able to compare this information. It was determined that there
was a difference between these time frames regarding illegal drugs versus legal medications,
but that there was not a difference between overall drug prevalence. For the weekday daytime
period, 11.3 percent of those in the survey group had illegal drugs in their system and 10.3
percent had only legal medications. For weekend nighttime drivers, 14.3 percent had illegal
drugs in their systems and 6.9 percent had only legal medications. This translates to an overall
incident rate of 21.6 and 21.2 percent, respectively (Berning, Compton & Wochinger, 2015).
To understand the importance of the present study, it is important to understand the
significance of the drugs selected for inclusion. A few are new additions to the OSBI laboratory
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LC/MS protocols and GC/MS libraries due to their appearance in at least one DUID case in
recent years. Most are drugs which have been shown to cause impairment in the average
person and are either seen often in casework or are not easily confirmed by GC/MS. Drugs are
commonly grouped into classes based on similarities in the structures and intended uses. Due
to this classification, similar psychomotor and cognitive affects are observed within a given
class.
In 2015, the most common drug class in OSBI Laboratory case work was
benzodiazepines. This group is one of the most widely prescribed in the world, replacing
barbiturates as the major central nervous system (CNS) depressant drugs. The most common
of these are alprazolam, lorazepam, clonazepam, diazepam and temazepam. There are
currently approximately twenty benzodiazepines approved by the United States Federal Drug
Administration (FDA). Benzodiazepines are prescribed as muscle relaxants, anesthetic adjuncts,
anticonvulsants, treatment for obsessive-compulsive disorder, and for anxiety. The time it
takes for the concentration of the drug in the blood to reduce by one-half, due to metabolism
in the body, is known as the half-life. The half-lives for these drugs range from one hour to four
days. The therapeutic range varies from two nanograms per milliliter (ng/mL) to four
milligrams per milliliter (mg/mL) in the blood.
The core chemical structure for the benzodiazepine class consists of a benzene ring
fused with a diazepine ring. This structure, as well as the structures for the benzodiazepines
included in the developed methods can be seen in Figure 2. Benzodiazepines can have
significant effects on psychomotor function, even at the recommended dose. These effects
include: prolonged reaction times and impaired judgment, coordination, alertness,
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concentration, and/or short-term memory. Clinical studies have shown that typical doses of
many benzodiazepines can impair some necessary driving skills. It has been noted that some of
the more polar drugs6 in this class do not elute well from common GC/MS columns. As LC/MS
has become more readily available, it is often selected for benzodiazepine analyses due to its
high sensitivity and high specificity for the more polar and thermally reactive compounds
(Levine & Jufer-Phipps, 2013).
Amphetamines, as well as other phenethylamine compounds, are commonly
encountered in Oklahoma7.  The base structure for this class is amphetamine. The structure for
amphetamine as well as all other amphetamines included in these methods can be seen in
Figure 3.  This growing class of compounds stimulates the sympathetic nervous system.  These
drugs were originally used as CNS stimulants for the treatment of narcolepsy and depression.
Their ability to alleviate fatigue, improve performance of simple mental and physical tasks,
elevate mood, and increase confidence has led to their abuse.  Methamphetamine is easily
synthesized in home (clandestine) laboratories, resulting in easy procurement and a larger
abuse problem.  Slight changes in the molecular structure have created “designer”
amphetamines which include, 3,4-methylenedioxylmethamphetamine (MDMA), methylone,
ethylone and methiopropamine.  MDMA is one of the oldest, whereas methylone, ethylone,
and methiopropamine have appeared in the past quarter century.  This class of drugs is known
as CNS stimulants.  Some classic symptoms of these drugs include: tachycardia, hypertension,
insomnia, nausea, and anxiety.  Currently, amphetamine is still commonly prescribed to treat
6 a compound in which the electric charge is not symmetrically distributed, so that there is a separation of charge
or partial charge and formation of definite positive and negative poles
7 This is based on 2015 OSBI Laboratory statistics where at least 21% of all DUID cases had, at a minimum, a
presumptive positive for phenethylamines.
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Base structure for benzodiazepines
Midazolam Flurazepam Temazepam Oxazepam
Clonazepam Nordiazepam Lorazepam Alprazolam
Flunitrazepam Diazepam Prazepam Chlordiazepoxide
Figure 2. Benzodiazepine chemical structures.
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attention deficit disorder (ADD) and attention deficit hyperactive disorder (ADHD).  Drugs in this
class are also commonly used for appetite suppression.  At low doses methamphetamine
induced CNS stimulation manifests as euphoria, alertness, intensified emotions, increased
feeling of self-esteem and well-being, and sensations of extreme physical and mental power.
After peak concentration is reached, the user may feel exhausted, disorganized, tense and
paranoid (Merves & Moore, 2013).
Methamphetamine Amphetamine Methylone Ethylone
MDMA Phentermine Methiopropamine
Figure 3. Amphetamine chemical structures.
Opiates, also known as opioids, have been in use for over two thousand years and are
naturally occurring analgesics from the opium poppy, Papaver somniferum. Opioids work by
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blocking the transmission of pain stimuli from the spinal cord to the brain and can also produce
euphoria in some cases. In the 20th century, synthetic opioids were synthesized to replace
morphine. Methadone, dextromethorphan and tramadol are examples of synthetic opioids
(see figure 4). They are often used for the management of chronic pain related to cancer and
terminal illness and can also be used for their sedative properties. It is common for those
taking opioids to become physically dependent on them and develop increasing tolerance
necessitating higher doses to obtain the same therapeutic effect. Methadone is often used for
detoxification of heroin addicts due to the milder withdrawal symptoms associated with this
compound.
Dextromethorphan is an analogue of codeine and is only used for its antitussive (cough
relief) effects. Tramadol is used in a similar fashion to codeine but is said to have less abuse
potential. Due to their CNS depressant effects, opioids have been shown to cause some level of
impairment in the average driver. These effects include but are not limited to: drowsiness,
lethargy, altered sensory perception, pupil constriction, droopy eyelids, slow driving, poor
coordination, delayed reactions and difficulty following instructions. LC/MS extractions allows
for the separation of both the free and deuterated drug8 without derivatization, and
simultaneous measurement of the parent drug and its metabolites. All of this is accomplished
with minimum sample preparation (Kerrigan & Goldberger, 2013, Baselt, 1982).
8 A compound in which the ordinary isotope of hydrogen has been replaced with deuterium.
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Codeine Oxycodone 6-MAM Hydrocodone
Methadone Dextromethorphan Tramadol N-
desmethyltramadol
Figure 4. Opioid chemical structures.
The major CNS depressant categories are barbiturates and benzodiazepines. However,
other CNS depressants which do not fit in these categories have been developed (see Figure 5).
Such drugs were originally created because they were believed to have advantages over
barbiturates and benzodiazepines. Carisoprodol, meprobamate, zolpidem, and cyclobenzaprine
all fall in this category. Carisoprodol is used as a muscle relaxer. Meprobamate was originally
developed as an alternative for barbiturates, but was found to produce toxic effects similar to
sedative-hypnotic drugs. It is also a metabolite of carisoprodol. Cyclobenzaprine is also used as
a muscle relaxer with a therapeutic range of ten to thirty nanograms per milliliter of blood.
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Zolpidem was a prototype for a class of sedative-hypnotic drugs. It possesses similar effects to
benzodiazepines, but is not considered one due to structural differences. Zolpidem is currently
used for short-term management of insomnia with an elimination half-life of a few hours
(Levine, 2013).
Carisoprodol Meprobamate Zolpidem Cyclobenzaprine
Figure 5. Miscellaneous CNS depressant structures.
Antihistamines are common place in almost any location.  These drugs are used to
relieve or prevent symptoms of allergies by preventing the effects of histamine.  Some of these
can cause the average person to feel impaired while not affecting others.  Diphenhydramine,
also known as Benadryl, is one of the most commonly encountered in the forensic toxicology
world (see Figure 6).  Diphenhydramine can cause CNS depression, slowed response, reduced
attention, and drowsiness.  The average therapeutic range for these drugs is 20 to 30
nanograms per milliliter of blood (Levine, 2013).
Approximately nineteen million people are affected by depression every year
(Anderson, 2013).  This would suggest that antidepressants are widely used and require
different therapeutic doses to meet patent needs.  Tricyclic antidepressants (TCAs), for example
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Figure 6. Antihistamine chemical structure.
amitriptyline, have significant side-effects, which include: dizziness, sedation, blurred vision,
and short-term memory impairment, as well as narrow therapeutic indices (see Figure 7).
Second-generation antidepressants are represented by trazodone in the current study.
Trazodone can be quite sedating in vivo and can cause drowsiness, confusion, incoordination,
and fatigue. All antidepressants are well absorbed and reach peak levels between two and
twelve hours after introduction. Due to the polarity of these medications, LC/MS allows for
their detection at low levels (Baselt, 1982).
Amitriptyline Nortriptyline Trazodone
Figure 7. TCA chemical structures.
Diphenhydramine
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Cocaine is a psychotropic9 drug that has been used for approximately two thousand
years.  In 2004, it was found that almost fifteen percent of Americans had tried cocaine and
that approximately two million were current users.  Cocaine hydrochloride is usually introduced
by insufflation, whereas crack cocaine, a form of the base, is often smoked to maximize the
high. The drug is used legitimately as a topical local anesthetic or vasoconstrictor. Cocaine can
affect coordination skills, reaction time, risk taking, mental health and result in fatigue
(Isenschmid, 2013). It is known to continue to be metabolized into benzoylecgonine (BE) and
ecgonine methyl ester (EME) which are evident in a blood draw (see Figure 8). Many
laboratories refrigerate samples and request that samples are collected in tubes containing
sodium fluoride and potassium oxalate to slow down the hydrolysis10 process which results in
methyl benzoate. LC/MS is beneficial for the analysis of cocaine and benzoylecgonine without
derivatization in a single analysis (Isenschmid, 2013).
Cocaine Benzoylecgonine Ecgonine Methyl Ester
Figure 8. Psychotropic drug chemical structures.
9 A psychotropic drug is one that changes the brain function and results in alterations in perception, mood, or
consciousness.
10 Chemical breakdown of a compound due to a reaction with water.
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There are many drugs that can cause hallucinations at high concentrations, however;
there is also a group of drugs that often result in a state of altered perception when taken.  This
group of drugs is known as psychedelic agents and contains the well-known drug phencyclidine
(PCP).  PCP was first synthesized in 1926, but its use as an anesthetic was not discovered
until 1956 (see Figure 9). Shortly after, the adverse psychological reactions which include,
delusions, delirium, hallucinations, and seizures were observed. Currently, PCP can be taken
orally, intravenously, and has also been seen as a liquid that tobacco or marijuana cigarettes
are dipped in before smoking. When smoked, peak effect is reached around thirty minutes
with residual effects for four to six hours. PCP exhibits stimulant, depressant, hallucinogenic,
and analgesic properties, but is classified as a dissociative anesthetic11. Some common side-
effects experience by those using PCP include: tremors, incoordination, dissociation, amnesia,
repetitive motor movements, hypnotic state, and tunnel vision (Jenkins 2013). It has also been
reported that people under the influence of PCP tend to remove their clothing because they
feel hot due to an increase in body temperature resulting from metabolism of the drug.
Phencyclidine
Figure 9. PCP chemical structure
11 A form of general anesthesia, but not necessarily complete unconsciousness, characterized by catalepsy,
catatonia, and amnesia.
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Materials and Methods
Chemicals and Reagents
All compound standards were purchased from Cerilliant Corporation (Round Rock,
Texas). All reference standards were of ≥ 98% purity. Formic Acid and Acetonitrile were
purchased from Fisher Scientific (Pittsburgh, Pennsylvania). 100 millimolar (mM) phosphate
buffered saline (PBS - pH 7.0) was purchased from Immunalysis (Pomona, California). The
bovine blood used for method development was obtained from Lampire Biological Laboratories
(Pipersville, Pennsylvania).
Preparation of Standard Solutions
Drugs that required optimization12 were diluted in deionized (DI) water to a
concentration of either 10 micrograms per milliliter (µg/mL) or 100 ng/mL and stored between
2-8°C. A working solution in deionized water containing all but the deuterated compounds at
concentrations ten times those listed in Table 3 was made and stored between 2-8°C. Appendix
5 includes a copy of the first draft of the OSBI protocol for the 250 µL method.  It also includes a
copy of a deviation that outlines how the low and high positive controls were made. The high
positive control was originally set at twenty times the low positive control. It was observed that
this concentration overloaded the column, so the high positive control concentration was
reduced to ten times the low positive control in the deviation. An internal standard13 (ISTD)
solution, including the three deuterated standards, was prepared in acetonitrile and stored
12 An act, process, or methodology of making something (as a design, system, or decision) as fully perfect,
functional, or effective as possible. In this context, it refers to determining the most efficient parameters for each
drug when analyzed by LC/MS-MS.
13 A chemical substance that is added in a constant amount to all samples, besides blanks, to verify that the
instrument is working properly. This substance should not be one that is being analyzed for. Deuterated
compounds are often used.
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between -18 and -22°C following the protocol in Appendix 5. These standards were chosen due
to their retention times – one early, one middle, and one late eluter. This demonstrates that
the instrument is functioning properly throughout the entire analysis. The concentration of
ISTD in the solution is approximately 100 ng/mL. This was diluted 1:3 with acetonitrile for the
100 µL extraction to adjust for the lower concentration of drugs. The ISTD concentration was
set based on the lower limit set for the drugs in the method. 100 ng/mL was decided on
because it would not be too high or too low compared to the other compounds, which range
from 10 to 500 ng/mL of blood.
LC /MS-MS Conditions
The LC/MS-MS used was a Schimadzu LCMA-8030 triple quadruple system. The
chromatographic column was a Kinetex C18 column (75mm x 2.1mm x 2.6µm), which was
maintained at a temperature of 60° C with a flow rate of 0.800 milliliters per minute (mL/min).
The mobile phase14 was composed of solvents A (0.1% formic acid in deionized water) and B
(0.1% formic acid in acetonitrile). The gradient15 used is shown in Table 1. The sample injection
volume was 20 µL. The nebulizing gas16 flow was 2 liter per minute (L/min). The desolvation
line17 and heat block18 temperature was 225°C. The drying gas19 flow was 20 L/min and the
entire run time was six minutes. All conditions were selected based on their use in the
previously validated benzodiazepine and opiate methods currently in use at the OSBI. The
14 Solvent used to move the sample through the column.
15 The concentration of the solutions in the mobile phase changes over time.
16 Gas used to transfer ions from the liquid phase to the gas phase before entering the mass spectrometer.
17 Used to introduce the vaporized ions into the mass spectrometer.
18 Used to heat the desolvation line.
19 Used to prevent solvent clusters and promote better chromatography and complete vaporization of the sample
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Table 1
Gradient used in current study







internal standard used for each compound, multiple reaction monitoring (MRM) transitions20,
volts used for each compound, and retention times are shown in Table 2.  MRM transitions are
used to differentiate drugs from one another by using a parent and product ion that is normally
unique to each drug.  For example, the MRM transitions for codeine are 300.10 to 198.80 and
165.15.  300.10 is the parent ion, while 198.80 and 165.15 are the product ions.  If two drugs
have similar molecular weights, they may have one similar product ion. For example, the
parent ion for methamphetamine is 150.20 and the parent ion for phentermine is 150.10. The
first product ion for both is 91.10 and 91.00, respectively. If this is the case, then a unique
product ion will also be required. The unique product ion for methamphetamine is 119.10 and
133.10 for phentermine.
20 Parent ion to product ion used for identification.
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The parent and product ions for each internal standard can be seen in Table 2. The
internal standard is used to standardize quantitation results between injections to negate
differences in injection efficiency. They are also used to verify that the instrument is
functioning properly throughout the analysis. This is accomplished by comparing the retention
time of the internal standards in the case samples to the retention time of the internal
standards in the control samples. If there is a significant change in the retention time, then
maintenance is likely needed and the case and control samples will need to be reanalyzed. The
information for columns 4, 5, and 6 in Table 2 will be discussed in more detail on pages 26, 27,
and 28.
Table 2















Pseudoephedrine 0.77 166.10>148.05 -15 -13 -14 Methamphetamine-
d8
166.10>91.00 -15 -33 -19
166.10>132.95 -15 -23 -13
Methiopropamine 0.78 156.20>96.95 -13 -23 -21 Methamphetamine-
d8
156.20>58.00 -13 -13 -10
156.20>125.10 -13 -16 -28
Methylone 0.88 208.00>160.05 -17 -2 -16 Methamphetamine-
d8
208.00>132.05 -17 -27 -29
208.00>190.05 -17 -13 -19
Codeine 0.88 300.10>198.80 -16 -32 -15 Methamphetamine-
d8
300.10>165.15 -16 -43 -15















Amphetamine 0.93 136.20>91.10 -11 -18 -15 Methamphetamine-
d8
136.20>119.10 -12 -15 -12
136.20>65.10 -12 -41 -24
Oxycodone 1.01 316.10>174.90 -16 -35 -14 Methamphetamine-
d8
316.10>212.00 -16 -45 -21
Methamphetamine-
d8
1.03 158.00>92.95 -14 -23 -14 Methamphetamine-
d8
158.00>66.10 -13 -46 -28
158.00>124.00 -13 -15 -12
Methamphetamine 1.04 150.20>91.10 -12 -22 -17 Methamphetamine-
d8
150.20>119.10 -12 -15 -11
Ethylone 1.06 222.20>173.95 -12 -20 -17 Methamphetamine-
d8
222.20>204.00 -12 -14 -21
222.20>146.00 -12 -28 -15
6-MAM 1.07 328.10>165.00 -17 -46 -17 Methamphetamine-
d8
328.1>211.20 -17 -26 -22
Hydrocodone 1.09 300.10>198.85 -15 -30 -20 Methamphetamine-
d8
300.10>171.00 -15 -40 -20
MDMA 1.09 194.00>163.10 -11 -13 -16 Methamphetamine-
d8
194.00>105.15 -11 -27 -22
194.00>77.10 -11 -45 -14
Caffeine 1.11 195.00>138.00 -17 -22 -29 Methamphetamine-
d8
195.00>42.00 -17 -40 -16
195.00>110.00 -11 -25 -25
Phentermine 1.18 150.10>91.00 -12 -22 -20 Methamphetamine-
d8
150.10>133.10 -12 -14 -29
Benzoylecgonine 1.33 290.00>168.00 -15 -20 -16 PCP-d5
290.00>105.00 -15 -35 -21
Tramadol 1.49 264.30>58.15 -11 -35 -13 PCP-d5
264.30>42.00 -15 -50 -15

















1.50 250.00>44.00 -10 -13 -18 PCP-d5
Cocaine 1.58 304.00>182.05 -16 -20 -19 PCP-d5
304.00>81.95 -16 -33 -17
304.00>105.10 -16 -35 -23
Zolpidem 1.75 308.00>235.00 -23 -35 -24 PCP-d5
308.00>263.00 -23 -25 -27
Meprobamate 1.80 219.10>158.15 -16 -10 -16 PCP-d5
219.10>97.15 -12 -16 -21
Chlordiazepoxide 1.86 299.90>227.10 -25 -25 -23 PCP-d5
299.90>283.15 -25 -14 -19
Trazodone 1.9 372.10>176.2 -15 -25 -17 PCP-d5
372.10>148.05 -16 -38 -15
372.10>78.15 -15 -54 -17
PCP-d5 2.00 249.30>86.15 -10 -25 -21 PCP-d5
PCP 2.01 244.20>86.20 -13 -13 -18 PCP-d5
244.20>91.15 -13 -32 -20
244.2>159.20 -22 -15 -16
Dextromethorphan 2.18 272.15>147.05 -14 -35 -15 PCP-d5
272.15>171.05 -14 -40 -17
Diphenhydramine 2.3 256.00>167.10 -14 -12 -17 PCP-d5
256.00>152.10 -14 -40 -15
256.00>165.10 -14 -40 -16
Midazolam 2.31 326.00>291.00 -12 -30 -30 PCP-d5
326.00>244.00 -12 -25 -26
Flurazepam 2.49 387.90>315.00 -15 -25 -21 PCP-d5
387.90>288.00 -15 -25 -30
Cyclobenzaprine 3.06 276.05>215.10 -22 -40 -22 PCP-d5
276.05>84.10 -11 -25 -16
Temazepam 3.17 301.20>255.00 -24 -25 -18 Prazepam-d5
301.20>283.00 -24 -15 -21
Nortriptyline 3.21 264.15>233.05 -21 -15 -26 PCP-d5
264.15>218.00 -21 -26 -25
264.15>91.00 -21 -23 -10
Oxazepam 3.27 287.00>241.00 -15 -24 -27 Prazepam-d5
287.00>269.00 -15 -18 -19
Amitriptyline 3.33 278.40>105.00 -14 -20 -22 Prazepam-d5
278.40>233.05 -14 -15 -26















Clonazepam 3.42 316.00>270.00 -12 -30 -29 Prazepam-d5
316.00>214.00 -12 -45 -22
Methadone 3.44 310.02>265.15 -17 -16 -27 Prazepam-d5
310.02>105.00 -13 -28 -10
310.02>57.10 -13 -25 -23
Nordiazepam 3.45 270.9>140.00 -20 -30 -14 Prazepam-d5
270.90>165.00 -20 -30 -18
Lorazepam 3.51 321.00>275.00 -12 -20 -29 Prazepam-d5
321.00>229.00 -12 -30 -23
Carisoprodol 3.62 261.00>158.20 -22 -10 -16 Prazepam-d5
261.00>97.10 -14 -20 -22
Alprazolam 3.64 309.00>281.00 -12 -30 -29 Prazepam-d5
309.00>205.00 -12 -45 -22
Flunitrazepam 3.75 314.00>268.00 -12 -30 -29 Prazepam-d5
314.00>239.00 -12 -45 -22
Diazepam 3.93 285.00>154.00 -12 -30 -29 Prazepam-d5
285.00>193.00 -12 -45 -22
Prazepam 4.32 325.00>271.05 -24 -25 -28 Prazepam-d5
325.00>140.00 -24 -40 -28
Prazepam-d5 4.33 330.00>276.00 -10 -24 -29 Prazepam-d5
330.00>140.00 -10 -39 -14
Sample Preparation
For the original extraction: in a micro-centrifuge tube (Figure 10), whole blood samples
(225µL) were spiked with 25µL of low or high positive control21 to serve as controls. 250 µL of
sample was transferred to a micro-centrifuge tube for all test samples. Acetonitrile containing
internal standards22 (500 µL) is then added, vortexed well for thirty seconds, then centrifuged
at approximately 13,000 rotations per minute (RPM) for five minutes. The acetonitrile layer
21 Contains a known amount of analyte and verifies that the instrument is capable of identifying each compound.
The low control is set at the bottom of the therapeutic range and the high control is twenty times higher.
22 The internal standard/acetonitrile mixture is created by pipetting 50 microliters of each 100 µg/mL primary
deuterated standard into a 250 milliliter volumetric flask and filling to the line with acetonitrile.
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was then transferred to a centrifuge tube and evaporated at 40°C with a stream of dry nitrogen.
Finally, the sample was reconstituted with 100 µL of reconstitution solvent.
Figure 10.  Micro-centrifuge Tube
For the low-sample-volume extraction: in a micro-centrifuge tube (Figure 10), whole
blood samples (90 µL) spiked with 10 µL of low or high positive control to serve as controls. 100
µL of sample was added to a micro-centrifuge tube for all test samples. 100 µL of PBS buffer
(pH 7) was added. Acetonitrile containing internal standards (500 µL) is then added, vortexed
well for thirty seconds, then centrifuged at approximately 13,000 RPM for five minutes. The
acetonitrile layer was then transferred to a centrifuge tube and evaporated at 40°C with a
stream of dry nitrogen. Finally, the sample was reconstituted with 100 µL of reconstitution
solvent.
Method Development and Validation
The original goal for this extraction was to be able to take a portion of the sample used
for a presumptive drug screen using enzyme-linked immunosorbent assay (ELISA) and extract it
for use as a confirmatory test using the LC/MS-MS. However, this was revamped when it was
found that the SOFT/AAFS Forensic Toxicology Laboratory Guidelines recommended that
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separate aliquots of sample should be used for presumptive and confirmatory testing, to lessen
the chance of reporting out contaminated results.
8.2.7 It is good practice to confirm the identity of an analyte in a different extract of the
sample specimen from that used for the test, or in a second specimen. However,
confirmation of a drug or toxin in the same original extract of a single specimen would
not normally be regarded as acceptable, since that would not rule out the possibility
that the extract became contaminated during the extraction or that the wrong sample
was tested (2007).
The choice of drugs for the exploration of this method were chosen by both the OSBI
Toxicology Unit Technical Manager as well as a survey of the most common drugs seen in
casework at the OSBI in recent years. This resulted in an initial list of forty-six drugs including
three deuterated internal standards. During the optimization process, three of the drugs were
dropped, zaleplon, phenazepam, and estazolam, due to poor response. The product ions were
too small to be used for the MRM and, therefore, were not viable options for this method. The
process of optimization will be discussed in detail later. During the validation process for the
lower sample volume extraction, it was noted that zopiclone did not extract with the proposed
method so it was also dropped. This was verified by opening the window for analysis to the
length of the entire run to confirm that it was not eluting earlier or later than previously
determined in the 250 µL extraction method. The end result was a list of forty drugs and three
internal standards that could be detected using the 250 µL extraction method and thirty-nine
drugs and three internal standards using the 100µL extraction. In addition, caffeine is also in
the method, but was not validated because it is not regularly reported in toxicology cases and
there was a lack of blank blood for validation purposes.
DRUG IDENTIFICATION AND CONFIRMATION BY LC/MS-MS 26
The limit of detection for the instrument is lower than the therapeutic range, so the
concentration for the low positive control for each drug was administratively assigned based on
known therapeutic ranges and suggestions from articles authored by well-known toxicologists
(Logan, Lowrie, Turri, Yeakel, Limoges, Miles, & Farrell, 2013; Winek, Wahba, Winek Jr., &
Winek Balzer, 2000). These are listed in Table 3.
Bovine blood was originally used for method development in accordance with OSBI
policy.  Once the method was developed, blank human blood case samples that had been set to
be destroyed were used for validation and method comparisons.  All identifying information
was not recorded to maintain anonymity.  These samples were first analyzed by GC/MS and the
methods in development to verify that they did not contain any of the drugs of interest.  The
250 µL extraction procedure was developed first to meet case load requirements at the OSBI.
Once this method was validated following the Scientific Working Group for Forensic Toxicology
(SWGTOX) guidelines, a method was validated using a smaller sample volume mixed with
phosphate buffer.
All new compounds were optimized.  This was accomplished by injecting the sample and
checking for the precursor ion23.  The new compounds were injected as a neat sample at a
concentration of 100 ng/mL.  An example of this can be seen in Figure 11.  This was achieved by
diluting a 1 mg/mL standard at a 1:99 ratio with deionized water to create a 10 µg/mL solution.
This solution was then diluted again using a 1:99 ratio with deionized water to create a 100
ng/mL solution.  Next, the most efficient voltage for focusing this ion is selected and the
23 Also known as a parent ion which may be a molecular ion or an electrically charged fragment of a molecular ion.
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Table 3.





Pseudoephedrine 100 Phencyclidine 10
Methylone 20 Dextromethorphan 20
Codeine 10 Diphenhydramine 25
Amphetamine 10 Midazolam 50




Methamphetamine 20 Temazepam 20
Ethylone 20 Nortriptyline 25
6-MAM 5 Oxazepam 20
Hydrocodone 10 Amitriptyline 25
MDMA 20 Clonazepam 10
Caffeine 50 Methadone 20
Phentermine 20 Nordiazepam 20
Benzoylecgonine 50 Lorazepam 10
Tramadol 20 Carisoprodol 500
N-desmethyltramadol 20 Alprazolam 10
Cocaine 10 Flunitrazepam 10
Zolpidem 10 Diazepam 20
Meprobamate 500 Prazepam 10
Chlordiazepoxide 50 Prazepam-d5 80
Trazodone 25 Methiopropamine 10
PCP-d5 80 Zopiclone 50
collision energy is determined through testing multiple options and selecting the most efficient
(between 0 and -50 volts). Examples of this can be seen in Figures 12 and 13. If the most
efficient focusing energy for Q1 is set correctly, then only the parent ion will be visible in the
spectra in Figure 12.  Figure 13 illustrates how the parent ion breaks at each collision energy
level.  The analyst will then determine which product ions are the most common among all
collision energies and those will be chosen for use in the method. The focusing voltage will
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allow only the parent ion to continue into the collision cell and the collision energy is what will
break the parent ion into the product ions. This is indexed in 5 volt increments. Afterward, the
analyst picks the product ions and the instrument focuses the product ions in the final
quadrupole. An example of this can be seen in Figure 14. This requires a voltage determination
for the final quadrupole as well and an example can be seen in Figure 15. The final results of
the optimization can be seen in Figure 16. The top line shows the peak area of the transition
between the parent ion and the most abundant product ion. In this case, it is 222.20 to 173.95.
The next line down is the second most abundant which would be 222.20 to 204.00. The blue
line is the third most abundant which is 222.20 to 146.00. The rest do not have enough of a
response to warrant their use in the method. The voltages used in each step for the individual
compounds can be seen in Table 2.
As illustrated in Figure 17, quadrupoles use an electro-magnetic field to isolate the
target compound and move it through the mass spectrometer.  The collision chamber breaks
the precursor ions into reproducible fragments. They then travel into the final quadrupole
where the selected product ion(s) are directed to the detector.  The information obtained
through optimization is used to create a method that will then be modified regarding retention
times, gradients, and cycle times throughout the method development phase.
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Figure 11. Step 1 of optimization, determination of parent ion.
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Figure 12. Step 2 of optimization, determination of Q1 voltage.
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Figure 13. Step 3 of optimization, determination of collision energy voltage.
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Figure 14. Step 4 of optimization, selection of most common product ions.
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Figure 15. Step 5 of optimization, determination of Q3 voltage.
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Figure 16. Results of optimization.
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Figure 17. Schematic of a LC/MS-MS. Based on Schimadzu (n.d.)
Once a starting gradient and cycle time have been selected, all drugs are analyzed using
this method to determine their retention time and to observe their location compared to other
compounds. The starting gradient and length of analysis for these methods was based off of a
previously developed benzodiazepine method since all compounds from that method were to
be analyzed in the methods currently being developed. It was noted that methamphetamine
and phentermine did not have sufficient separation (Figure 18).  The red line represents
methamphetamine and the blue line represents phentermine.  As mentioned previously, both
have similar parent and first product ions which means that adequate separation is required if
the method is to be used for quantitation in the future.  The gradient was adjusted to allow for
better separation.  The gradient developed for the method being validated can be seen in Table
1. A gradient can be modified in two ways.  The first option is by lengthening the time taken to
reach a new mixture percentage, i.e. setting the instrument to require two minutes instead of
one minute to adjust from a 95:5 mobile phase A:mobile phase B mixture, to an 80:20 mixture.
DRUG IDENTIFICATION AND CONFIRMATION BY LC/MS-MS 36
The second is to changing the percentage of the mixture in a certain time period, i.e. instead of
moving from 95:5 mobile phase A:mobile phase B mixture to an 80:20 mixture, adjust to a
75:25 mixture. To obtain the most efficient gradient, multiple samples must be analyzed while
adjusting the gradient slightly between each injection until separation is achieved. Figure 19
illustrates the results of the gradient adjustment regarding methamphetamine and
phentermine, the first and second peak, respectfully.
Figure 18. Coelution of methamphetamine and phentermine
Figure 19. Separation of methamphetamine and phentermine.
The percent of each component making up the mobile phase (mobile phase
components can be found on page 18) was determined using previously developed methods as
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well as troubleshooting injections.  This consisted of adjusting the percentages slightly and
injecting neat standards until the most efficient mixture was determined.  Once this was
completed, the retention times were obtained for all compounds. Retention times are
determined by setting the window of analysis for each compound to the entire length of the
run. An extracted spiked sample was analyzed, the MRM transitions for each compound were
reviewed and the retention time recorded. The window of analysis of each compound was
then established. According to OSBI policy, the retention time for each control and sample
must be within 0.15 minutes of the retention time observed for the low positive control. It is
important to note the retention time window is something that can be adjusted based on drift
that may result from the age of the column or slight differences between mobile phase batches,
but it should not drift more than 0.15 minutes.
At this point, the potential blank human blood samples were extracted using the
developed method to verify that they were indeed blank. It was determined that not all of
these samples were drug free so more case samples that were set to be destroyed were
obtained and analyzed as mentioned above. Some samples were originally analyzed by GC/MS
only. When they were examined using the more sensitive LC/MS method, it was observed that
some had low concentrations of drugs that were undetectable when using a GC/MS scan
method.
The make-up of the reconstitution solvent was tested while the samples were being
procured. There were three original options with the ability to try more if necessary. These
consisted of de-ionized water and 0.1% formic acid with either a 9:1 or a 19:1 de-ionized water
to acetonitrile mixture. This was assessed by using all possible reconstitution solvents mixtures,
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to reconstitute an extraction of 225 µL bovine blood spiked with 25 µL of positive control. They
were each analyzed using the developed method for the LC/MS and the peak areas for each
compound were compared. There were no noticeable differences for each drugs of interest so
only the ones with significant differences were reviewed to determine the most efficient
reconstitution solvent. It was found that 0.1% formic acid in 9:1 de-ionized water to
acetonitrile mixture worked best based on peak area response. It was also verified that the
temperature of the acetonitrile used for protein precipitation did not matter. Protein
precipitation will be discussed in more detail on page 39. This was tested by extracting samples
using room temperature acetonitrile as well as acetonitrile stored in the freezer. There were no
apparent differences in the resulting peak area.
It was noted that the benzodiazepines appeared to be suppressed due to their retention
time being the same as carisoprodol which had a much higher cutoff concentration. The dwell
time was adjusted to try and remedy this issue. The dwell time refers to the amount of time
that the instrument analyzes for each drug individually. These are often very short periods of
time. For the drugs that have a much higher concentrations, i.e. carisoprodol and
meprobamate, the dwell time was set for 5 milliseconds (msec). For the benzodiazepines that
eluted around the same time as carisoprodol, the dwell time was set for 50 milliseconds (msec).
For all other drugs, the dwell time was set for 25 msec.
Once the method was developed, three internal standards were selected to span the
range of anticipated retention times. Methamphetamine-d8, phencyclidine-d5, and prazepam-
d5 were selected as an early, middle and late eluter, respectively. Methamphetamine-d8 elutes
at approximately 1.00 minutes, phencyclidine-d5 elutes at approximately 1.95 minutes and
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prazepam-d5 elutes at approximately 4.25 minutes. The length of the method developed was
approximately 5.5 minutes. This placed an internal standard in the group of early eluters, one
near the middle of the method and one right at the end of the method which allowed the
compounds of interest to be compared to an internal standard that eluted near the same time.
The use of internal standards is important because it allows for standardization between
injections for quantitation purposes. This works by using a ratio of the peak area of the internal
standard divided by the peak area of the drug of interest. Quantitation was not pursued in this
validation so additional information regarding this process was not relevant or included in this
paper. Internal standards also provide the ability to verify that there was no retention time
drift during analysis. Drift could be caused by a clog, a leak, or another maintenance issue.
Having internal standards in each control and sample allows the analyst to verify that none of
these issues occurred during analysis.
To verify that an acetonitrile protein precipitation extraction24 was the most appropriate
for this method a liquid-liquid extraction25 using borate buffer and chlorobutane was
completed. This extraction mixture was used for comparison because it is the validated alkaline
drug26 extraction for GC/MS used at the OSBI currently. This extraction was compared directly
to the protein precipitation extraction and it was found that 250 µL of sample extracted using
the protein precipitation method was both simpler and provided the best recovery. With this
completed, the method was validated by assessing the interference, carryover, limit of
24 The addition of an organic solvent, acetonitrile in this instance, causes the proteins in the samples to precipitate
out and create a “plug” at the bottom of the vial while keeping the compounds of interest in the liquid sample
which can then be poured off.
25 Extraction that uses basic and acidic reagents to move the drugs to a cleaner solvent that can be analyzed by
GC/MS or LC/MS.
26 This is a drug that has a pH greater than 7.  Also known as a basic drug.  This extraction also works for higher
concentrations of neutral drugs, carisoprodol and meprobamate for example.
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detection, and ion suppression and enhancement as acceptance criteria. These criteria are




Interference Studies Evaluate interference from compounds in all current LC/MS-
MS methods as well as other drugs commonly identified in
the toxicology laboratory.
Carryover Carryover after a high concentration sample must be less
than 20% of the mean decision point peak area.




Less than 25% suppression or enhancement and <15% %CV
due to matrix (if not, evaluate impact on LOD)
Possible matrix interferences were assessed by using ten previously analyzed blank
whole blood case samples which were extracted using the developed method. No internal
standards were added to these samples and no interferences were detected. Neat samples of
commonly encountered drugs were analyzed at a concentration of 100 ng/mL to verify that
there was no interference. Interference would be considered anything that results in a false
positive for a drug of interest. Carryover was tested by injecting an extracted spiked sample
that contained 20 times the concentrations listed in Table 3. Carryover results when a drug
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contained in one sample can be seen in a later sample.  This can be the result of the drug
requiring more time to pass through the column causing it to show in the next sample instead
of the original sample, contamination during any portion of the extraction or injection, a high
concentration of the drug which results in the compound remaining in the column and being
detected in other samples or any combination of the three. The extracted sample was injected
three times, each was immediately followed by a blank extraction. No carryover was observed.
The carryover extractions were prepared as described in sample preparation.
As mentioned previously, the limit of detection (LOD) was administratively set. This
was tested by completing three analytical runs, analyzed on different days or extracted by
different analysts, which consisted of three replicates. The matrices used were spiked blank
blood samples from previously analyzed cases.  As per OSBI policy, the ion ratios must be within
30% of the values set by the first sample of the run and the %RSD for retention times is less
than four percent (Appendix 2). The table in Appendix 2 contains the peak area and retention
time for all compounds for each replicate, as well as the ion ratio evaluated for precision.
For ionization suppression and enhancement, a post-extraction addition approach was
used. Ionization suppression and enhancement is a result of either a reduced or increased
response resulting from the extraction process. Two sets of ten blank samples were extracted.
A low and high concentration reconstitution solvent was created. The low concentration used
was double the concentrations listed in Table 3 and the high concentration was twenty times
the concentrations listed in Table 3. The neat reconstitution solvent was also injected six times
on the instrument. Results for each drug are listed in Appendix 2. Set one consists of the neat
standards and set two consists of the blank blood sources.
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ℎ (%) = 21 − 1 100
The example below is the calculation for methamphetamine:
Ionization suppression or enhancement (%) = [(3529187/4589072) – 1] * 100
Ionization suppression or enhancement (%) = [(0.7690415404) – 1] * 100
Ionization suppression or enhancement (%) = [-0.2309584596] * 100
Ionization suppression or enhancement (%) = -23.10
The method passed all of these requirements and was approved by the OSBI technical
manager to be used for casework. The validation plan and completed validation report can be
found in Appendices 1 and 2.
The development of a variation of this method facilitating smaller sample volumes was
the next step in this project.  First, the amount of sample and buffer needed was explored
alongside the same portion of blood without buffer, and one with water instead of buffer.  The
extractions are shown in Table 5.  It was found that 100 µL of sample mixed with 100 µL of
phosphate buffer provided the best recovery regarding pivotal compounds.  This conclusion
was based on a comparison of the peak areas of each drug of interest for each extraction.
There were not significant differences between extractions for all compounds, so only those
that did have significant differentiation were considered in the decision making process (see
Table 6).  It was noted at this time that zopiclone did not extract under these conditions.  A
chromatogram showing the low positive control for the 100µL extraction can be seen in figures
20, 21, 22, and 23.  Codeine, oxycodone, and 6-MAM are not visible in the chromatogram due
to their low peak height. However, their peak area can be seen in Table 7.  The instrument also
provides a close up of each compound using the post-run software.  This allows the analyst to
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Table 5











100 µL 100 µL _ 500 µL
100 µL _ 100 µL 500 µL
100 µL 400 µL _ 1000 µL
100 µL _ 400 µL 1000 µL
100 µL 900 µL _ 1000 µL
100 µL _ 900 µL 1000 µL
100 µL _ _ 250 µL
Table 6
Peak areas for key compounds for 100 µL method.




Methiopropamine 110451 16917 3549 8683
Codeine 6957 11613 13016 6240
Meth–d8 779488 105698 46367 70017
Methamphetamine 438323 55038 56867 72128
Phentermine 302219 29519 30227 41708
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verify the existence of a peak for each compound in the controls.  An example of this for
oxycodone can be seen in Figure 24.  After this verification was completed, the method passed
all validation requirements set by the SWGTOX guidelines.  The validation plan and completed
validation report can be found in Appendices 3 and 4.
Once the validation was complete, the method was tested for use for synthetic
cannabinoids and organic cannabinoids.  It was found that this method was not appropriate for
these compounds.  This was determined by spiking blank blood samples with a high
concentration of all synthetic and organic cannabinoids currently tested for by the OSBI. They
were extracted and analyzed using the 250 µL method.  It was found that both synthetic and
organic cannabinoids do not extract using the developed methods.  These compounds were
previously optimized for other OSBI methods which allowed them to be easily added to the
current method. The instrument was then programmed to analyze for all of the compounds for
the entire length of the method. The only observed peaks were those of the internal standards.
This would suggest that the synthetic and organic cannabinoids did not extract from the
samples using this particular method.
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Figure 20. Low positive control for 100 µL extraction.
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Figure 21. Close up of front third of Figure 20.
MDMA
Hydrocodone
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Figure 22. Close up of middle third of Figure 20.
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Figure 23. Close up of last third of Figure 20.
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Table 7. Compound table associated with Figure 20.
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Figure 24. Oxycodone peak in association with Figure 20.
Results
Thirty case samples, i.e. DUI case specimens that were set for destruction, were
analyzed using the newly developed methods for comparison with the results from the current
OSBI GC/MS extraction. These case samples were selected due to positive presumptive and
GC/MS results, or to verify negative presumptive results. Through this analysis, it was verified
that the LC/MS-MS method would be sensitive enough to be used instead of the GC/MS
method if required due to limited sample quantity. The results of this analysis are in Table 8.
The results show that the LC/MS-MS is more sensitive than the GC/MS. This is due to a couple
of factors. First, the GC/MS requires compounds to be semi-volatile, whereas the LC/MS does
Oxycodone peak
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not.  Second, the developed LC/MS method uses MRM while the GC/MS uses a scanning
method. MRM is discussed in more detail on page 4. By selecting to only analyze the sample for
certain ions, the background noise, and consequently the limit of detection are much lower
than those seen when using a scanning method.
The OSBI acceptance criteria for GC/MS is a 3:1 signal to noise ratio, a retention index
that is within 25 units of the library known, and a Gaussian shaped peak. A retention index
allows for comparison among instruments by using 24 straight chain hydrocarbons, known as a
hydrocarbon ladder, to create a unit-less number assigned to each compound based on their
retention time compared to the hydrocarbon ladder. This allows analysts to compare results
between two instruments as long as both have the same type of column. This would not be
possible if only retention time was used due to slight differences in the length of the column
due to maintenance performed during the life of the column. Gaussian peak shape refers to a
symmetrical peak shape.  The OSBI acceptance criteria for LC/MS-MS is mentioned on pages 37
and 41. All compounds that appear to be present by GC/MS, but not LC/MS, were not part of
the method because they are not known to cause impairment, are used as cutting agents, or
were less commonly seen metabolites of a drugs of interest, and were not selected for the
initial validation.
For the direct comparison study, many of the drugs were found in both LC/MS methods.
There were some that did not meet criteria in the dilution method so they were not reported
even if they appeared present.  The current OSBI requirement to report LC/MS-MS results are
symmetrical peaks, and that they meet the retention time and ion ratio requirements set in
policy as mentioned on pages 37 and 41.  There are multiple factors that could have caused
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Table 8
Results of comparison study between GC/MS and LC/MS-MS methods.
Sample























2 THC, Meth Negative Methamphetamine AmphetamineMethamphetamine
Amphetamine
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5 Carisoprodol 0.318 Negative Meprobamate Meprobamate
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this, including the fact that it is a dilution method as well as the fact that the samples used were
whole blood and may have experienced more of a matrix effect due to the limited amount of
sample
Concluding this section, two forms of a single method were developed, validated and
either have been or will be put into policy at the Oklahoma State Bureau of Investigation
Forensic Science Center (OSBI FSC). These methods will allow testing of limited case samples
and can be used when a presumptive positive is unable to be confirmed by GC/MS.
Discussion and Future Research
The general drug identification and confirmation by LC tandem MS used for a sensitivity
comparison for LC/MS-MS has been validated and approved for use. The methods were
verified by completing all SWGTOX requirements and approved for use by the OSBI Technical
Manager after all data was reviewed. A peak in the same range as pseudoephedrine was
observed, but when the retention time was compared to the positive control, it was
determined that it was not pseudoephedrine. This was remedied by narrowing the detection
window. All compounds that appear to be present by GC/MS, but not LC/MS, were not part of
the method because they are not known to cause impairment, are used as cutting agencies, or
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were less commonly seen metabolites of a drugs of interest, and were not selected for the
initial validation. They can be added in at a later date and include chlorpheniramine,
citalopram, dextrophan, doxylamine, and levamisole.
There are drugs that elute at the same time, however, this is not a problem in these
methods due to the fact the methods developed are qualitative in nature and each compound
is analyzed for by using their unique parent and product ion combinations. This allows for
differentiation between multiple drugs at the same time. The gradient was adjusted multiple
times to remedy this to no avail.
It is obvious that the phosphate buffer had some impact on the recovery of most of the
drugs in this method (see page 42). No testing was completed because the reasoning behind
this enhancement was outside the scope of this validation. However, there are two possibilities
that came to mind regarding this occurrence. Either the phosphate buffer helps partition the
drug out of the blood into the acetonitrile or it is enhancing the solubility of the drug in the
reconstitution solvent aiding in recovery.
This list of drugs currently in this method is by no means complete. New compounds
are constantly appearing in DUID cases that could and should be added to this method. Each
will require full validation, but should not require any change in method. Additional research
could be completed to obtain the true limit of detection for each compound in these methods.
There is the possibility of this method being used for quantitative purposes, but that would
require a new validation with true limits of quantification. This is also a validation that could be
costly due to the number of standards and deuterated standards that would be required for
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completion. An experiment of why the phosphate buffer helped with the 100µL extraction
could also be completed in the future.
There is a possibility that this method could be used in regards to dried blood samples.
To test if this would be possible, four 250 µL samples were tested with some positive results.
Two aliquots were spiked with the low positive control concentrations listed in Table 3 and two
were spiked with the high positive control concentration. The sample was then spread on a
designated portion of a plastic sheet and allowed to dry. Once the samples were dry one low
and one high concentration were either swabbed or scraped. The swab was wet with DI water
and then rinsed with 250 microliters of DI water that was placed in a micro-centrifuge tube for
extraction. The flakes from the scraped samples were placed in 250 µL of DI water and
vortexed. All samples were then extracted using the newly validated method. Most
compounds were seen at both the low and high concentrations.  It also appeared that scraping
resulted in better recovery, but was also a messy process and would not allow for a control to
be analyzed alongside. This could be followed up with more research and testing.
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VALIDATION PLAN
TOXICOLOGY UNIT // OSBI-FSC Laboratory
Scope: Drug Identification and Confirmation by LC/MS/MS
Matrix(ces): Blood
Analyte(s): See Attached List
Instrumentation: LC/MS/MS
Analytical Method(s): TX-34




Carryover: Carryover after a high concentration sample must be less
than 20% of the mean decision point peak area.
Interference Studies: Evaluate interference from compounds currently in TX-39 as
well as other drugs commonly identified in the toxicology
laboratory.
Ionization Suppression/Enhancement: Less than 25% suppression or enhancement and < 15% CV
due to matrix (if not evaluate impact on LOD)
Limit of Detection: A minimum of three samples per run of a fortified matrix
sample at the concentration of the decision points shall be
analyzed over three runs to demonstrate that all detection
and identification criteria are met.  Decision point
concentrations attached as an appendix to this document.
Limit of Quantitation: N/A
Precision: N/A
Processed Sample Stability: N/A
Dilution Integrity (if applicable): N/A
Other Information: These compounds will be evaluated for the above indicated performance areas
according to the current Toxicology Quality Manual.
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Drug Identification & Confirmation by LC/MS/MS
Validation Report
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has proven to be a
powerful tool for fast and reliable sample analysis in the OSBI toxicology lab.
Furthermore, it allows the lab the flexibility to further refine and expand assay
capabilities.
This document describes the validation for the identification and confirmation of many
drugs that screen positive by enzyme-linked immunosorbent assay. This validation
demonstrates that the procedure provides reliable results for the analysis of drugs
identified and that meet the acceptable criteria set for this application. The concentration
range of target compounds used in this validation was chosen to fit the recommended
scope and cutoffs for identification and confirmation as outlined in “Recommendations
for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities”,
Journal of Analytical Toxicology 2013;37:552–558. Concentration ranges of target
compounds not identified in this article were determined by commonly encountered
range of compound concentrations seen in casework or literature review.
The sample preparation steps, as well as instrumental settings for use with blood
matrices were assimilated from the TX-39 method.  The validation parameters were
assessed against the pre-defined requirements listed in Table 1.
In brief, the procedure is outlined below:
 Pipet 250 µL blood to a microcentrifuge tube
 Add 500 µL of acetonitrile containing internal standards
 Vortex approximately 30 seconds
 Centrifuge at 13,200 rpm for 5 minutes
 Decant supernatant to conical tube
 Evaporate to dryness
 Reconstitute in 100 µL of reconstitution solvent and inject 20 µL.
Table 1: Validation parameters to be assessed
Parameter Acceptance Criteria:
Interference Studies No interfering signal from matrix, internal standard, common drugs of
abuse, OTC drugs and prescription medication.
Carryover Carryover after a high concentration sample must be less than 20% of
the mean decision point peak area.
Limit of Detection The LOD is defined as the decision point.  Decision point concentrations
are attached as an appendix to this document.
Ionization Suppression/
Enhancement
Less than 25% suppression or enhancement and less than 15% CV due
to matrix (if not, evaluate impact on LOD)
Interference Studies
Matrix Interferences
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Ten independent sources of blank whole blood were secured from previously analyzed
cases to evaluate matrix interferences. The blank matrix samples were extracted without
the addition of internal standard and analyzed using the method.
Interference from Stable-Isotope Internal Standards
Isotopically-labeled compounds were assessed by analyzing a blank matrix sample
fortified with the internal standards and monitoring the signal of the compounds of
interest.
Interference from Other Commonly Encountered Compounds
This evaluation was accomplished by analyzing fortified matrix samples of the potential
intereferences.
Opiates and Related Tramadol, N-desmethyltramadol, methadone
Drugs of Abuse Amphetamine, cocaine, benzoylecgonine, methamphetamine,
phencyclidine, MDMA, ethylone,methiopropamine, methylone
Prescription Drugs Antidepressants (amitriptyline, Nortriptyline, Trazodone),
Benzodiazepines (lorazepam, alprazolam, midazolam,
clonazepam, nordiazepam, diazepam, oxazepam, estazolam,
flunitrazepam, temazepam, flurazepam, prazepam,
phenazepam, chlordiazepoxide), CNS depressants (zopiclone,
zaleplon and Zolpidem, carisoprodol, cyclobenzaprine,
meprobamate), CNS stimulants (caffeine and phentermine)
OTC Drugs Antihistamine (diphenhydramine), antitussive
(dextromethorphan), decongestant (pseudoephedrine)
Carryover
To evaluate carryover as part of method validation, blank matrix samples are analyzed
immediately after a high concentration sample (20 times the decision point concentration).  The
highest compound concentration at which no compound carryover is observed in the blank
matrix sample is determined to be the concentration at which the method is free from carryover.
This concentration was confirmed using triplicate analyses.
Ionization Suppression/Enhancement
The post-extraction addition approach was used to assess ionization
suppression/enhancement. Two different sets of samples are prepared and the compound peak
areas of neat standards are compared to matrix samples fortified with neat standards after
extraction.
Set one consists of neat standards prepared at a high and low concentration for each
compound (20x and 2x the decision point). The neat standards were injected a minimum of six
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times to establish a mean peak area for each concentration.  Results of the two concentrations
are presented in Table 2.
Set two consists of ten different matrix sources. Each blank matrix sample was extracted in
duplicate. After the extraction was complete, each blank matrix sample was then fortified to
either the low or high concentration with each compound. Each concentration set sample was
injected one time each.
The average area of each set was used to estimate the suppression/enhancement effect at
each concentration. The following equation was used to calculate the percentage of ionization
suppression or enhancement and % CV. Table 2 list the percentage of ionization suppression
or enhancement at each concentration for each compound.
[1] ℎ (%) = − 1 100
[1] Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS, B.
K. Matuszewski, M. L. Constanzer, and, and C. M. Chavez-Eng, Anal. Chem. 2003 75 (13), 3019-3030.
Table 2:  Ionization Enhancement/Suppression
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Pseudoephedrine Methiopropamine Methylone Codeine
Set 1 13852525.17 110349726 2296065 17622506 2290637 18234839 33918.5 254750.17
Set 2 12583398.9 82682647.7 1765213 12723779 1456584 11894243 19379.5 148279.6
[2] % EE/(Suppr) -9.16 -25.07 -23.12 -27.80 -36.41 -34.77 -42.86 -41.79
% CV 5.47 5.89 6.34 3.91 21.94 9.19 21.35 11.02
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Amphetamine Oxycodone 6-MAM Methamphetamine
Set 1 1904546.5 16926401.5 73073.5 486663.7 24297.7 145306.7 4589072 33372765
Set 2 1133193.8 9820558.8 40985.1 289929 16426.4 97489.1 3529187 24733391
[2] % EE/(Suppr) -40.50 -41.98 -43.91 -40.43 -32.40 -32.91 -23.10 -25.89
% CV 11.90 8.66 13.74 13.70 19.13 19.03 7.94 9.75
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Ethylone Hydrocodone Phentermine MDMA
Set 1 3400360.667 21666147 133390 965641.8 1642267 13108964 2376922 20831581
Set 2 2757540.8 16595573.7 92832.1 664413.2 1230867 10057445 2646265 19709605
[2] % EE/(Suppr) -18.90 -23.40 -30.41 -31.19 -25.05 -23.28 11.33 -5.39
% CV 9.57 32.79 20.82 11.55 34.93 21.00 12.11 9.08
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Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Caffeine BE Zolpiclone Tramadol
Set 1 263581.1667 2467634.17 629043 4319467 2188053 17103023 4307504 24048971
Set 2 3432164.7 4307611.7 757506 4560473 1874816 13794378 4452889 27107848
[2] % EE/(Suppr) 1202.13 74.56 20.42 5.58 -14.32 -19.35 3.38 12.72
% CV 86.36 64.04 7.80 3.87 7.69 8.33 4.39 12.76
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
n-Desmethyltramadol Cocaine Zolpidem Chlordiazepoxide
Set 1 4213810.667 26736781.5 2792170 22418767 1405156 12598208 1514264 13834679
Set 2 3272563 24454858.8 2806710 21340192 1372902 11418591 1301784 9444408.4
[2] % EE/(Suppr) -22.34 -8.53 0.52 -4.81 -2.30 -9.36 -14.03 -31.73
% CV 28.38 8.85 3.24 3.67 2.44 3.21 5.00 4.99
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Lo
w
High
Meprobamate Trazodone PCP Dextromethorphan
Set 1 4490350.5 29957402.5 2652914 15483975 3004426 18050022 1028149 8496406.5
Set 2 4571800.9 26995814.3 2159439 14058242 2839744 18209889 747476 6199230.1
[1] % EE/(Suppr) 1.81 -9.89 -18.60 -9.21 -5.48 0.89 -27.30 -27.04
% CV 8.54 3.74 31.80 3.57 8.46 30.77 6.57 31.64
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Lo
w
High
Diphenhydramine Midazolam Flurazepam Cyclobenzaprine
Set 1 20035599.33 71829470.8 1248496 7416501 2171229 17481742 951042 8082041.5
Set 2 15918815.6 64209294.1 1005633 8118957 1944670 15561369 325448 5152256.6
[1] % EE/(Suppr) -20.55 -10.61 -19.45 9.47 -10.43 -10.99 -65.78 -36.25
% CV 4.82 1.64 46.59 3.63 4.08 3.90 13.87 7.90
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Lo
w
High
Nortriptyline Oxazepam Amitriptyline Methadone
Set 1 1465160.5 12606794 476323 3954652 330989 2091380 6388399 61860756
Set 2 367318.5 5925154.7 314571 2256772 106431 1845257 3954256 46495890
[2] % EE/(Suppr) -74.93 -53.00 -33.96 -42.93 -67.84 -11.77 -38.10 -24.84
% CV 12.95 11.51 12.88 25.89 14.01 11.21 9.13 31.98
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Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Lo
w
High
Clonazepam Carisoprodol Lorazepam Nordiazepam
Set 1 51441.33333 263043.667 3737510 28882323 220439 2239290 254047 2168496
Set 2 33993.2 165929.5 3891659 26870569 198726 1598588 148501 1052152.7
[2] % EE/(Suppr) -33.92 -36.92 4.12 -6.97 -9.85 -28.61 -41.55 -51.48
% CV 13.76 17.49 2.52 2.89 14.24 10.82 33.53 41.07
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Alprazolam Flunitrazepam Temazepam Diazepam
Set 1 36675.66667 283536.333 130407 1257004 1226357 10578704 409482 1935233.3
Set 2 69031.2 367517.5 132050 1149772 1052148 3958305 223030 1826684.5
[2] % EE/(Suppr) 88.22 29.62 1.26 -8.53 -14.21 -62.58 -45.53 -5.61
% CV 8.59 6.02 3.14 4.23 21.52 72.93 5.96 2.75
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Prazepam Meth-d8 PCP-d5 Prazepam-d5
Set 1 300870 2535919.17 5818796 43262546 4496532 34825444 1816668 15300894
Set 2 120665.1 1297061.9 564219 4087310 518492 3603258 144351 864161
[2] % EE/(Suppr) -59.89 -48.85 -39.12 -63.67 -35.36 -63.93 -47.06 -74.12
% CV 11.81 11.45 15.92 26.01 17.83 28.68 15.01 21.82
2 % Enhancement/Suppression
Limit of Detection
Using the decision point concentration as the limit of detection is useful for qualitative and
quantitative methods.  For the mission of this laboratory, it is sufficient to define the LOD as the
value of an administratively-defined decision point to fit the recommendations for toxicological
investigation of drug-Impaired driving and motor vehicle fatalities, when available.
A minimum of three samples per run of a fortified matrix sample at the concentration of the
decision point shall be analyzed over three runs to demonstrate that all detection and
identification criteria are met see Table 3.
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Table 3: Decision Point Peak Area, Retention Times and Ion Ratios




















Run 1 Rep 1 16864 1.045 47664 3.573 102625 3.167 294131 0.919
Run 1 Rep 2 18650 1.044 60080 3.574 124799 3.17 331195 0.914
Run 1 Rep 3 16365 1.053 59394 3.572 99313 3.177 638121 0.919
Run 2 Rep 1 18470 1.045 38485 3.574 79060 3.164 177270 0.917
Run 2 Rep 2 14048 1.041 48367 3.574 80991 3.168 189851 0.911
Run 2 Rep 3 14786 1.052 43432 3.574 96627 3.167 186016 0.912
Run 3 Rep 1 13688 1.05 62389 3.574 120868 3.17 261943 0.927
Run 3 Rep 2 16061 1.046 52966 3.57 95758 3.165 370705 0.92
Run 3 Rep 3 13486 1.055 63058 3.575 77283 3.172 346814 0.923
Std Dev. 1958 0.005 8891 0.002 17124 0.003 142800 0.005
Average 15824 1 52871 4 97480 3 310671 0.918
%RSD 12 0.454 16 0.042 17 0.124 45 0.563




















Run 1 Rep 1 440554 1.301 3448441 3.458 1078718 1.821 48662 3.278
Run 1 Rep 2 466180 1.301 3468989 3.457 1262371 1.823 49199 3.278
Run 1 Rep 3 428655 1.3 3419365 3.456 11112632 1.824 51151 3.277
Run 2 Rep 1 476114 1.302 3064341 3.459 1135193 1.822 45964 3.278
Run 2 Rep 2 391275 1.301 3244407 3.459 1206963 1.822 43852 3.279
Run 2 Rep 3 513895 1.302 3550518 3.458 1249501 1.823 46788 3.279
Run 3 Rep 1 636523 1.302 3555857 3.456 1090740 1.821 48426 3.278
Run 3 Rep 2 553458 1.298 3369047 3.452 1046923 1.819 44280 3.273
Run 3 Rep 3 670872 1.303 3401113 3.457 1000558 1.825 43903 3.278
Std Dev. 95117 0.001 154753 0.002 3327483 0.001 2617 0.001
Average 508614 1 3391342 3 2242622 1 46913 3
%RSD 18 0.111 4 0.062 148 0.098 5 0.055
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Run 1 Rep 1 2264594 1.535 22125 0.887 318729 2.96 2910859 1.453
Run 1 Rep 2 2296968 1.537 18011 0.887 386097 2.962 2637883 1.455
Run 1 Rep 3 2241106 1.537 22800 0.89 304062 2.967 2611392 1.455
Run 2 Rep 1 2022308 1.536 15672 0.887 275186 2.958 2573722 1.453
Run 2 Rep 2 2143967 1.536 22761 0.881 284412 2.958 2606051 1.454
Run 2 Rep 3 2154520 1.538 18878 0.883 319608 2.96 2280326 1.456
Run 3 Rep 1 2558314 1.535 14773 0.899 327517 2.963 3175666 1.454
Run 3 Rep 2 2295055 1.533 22263 0.892 263566 2.956 3171614 1.451
Run 3 Rep 3 2436978 1.539 19686 0.893 249803 2.963 2740340 1.457
Std Dev. 159596 0.001 3070 0.005 41131 0.003 293447 0.001
Average 2268201 1 19663 0.888 303220 2 2745317 1
%RSD 7 0.116 15 0.613 13 0.113 10 0.122




















Run 1 Rep 1 606840 2.092 197388 3.916 102625 3.167 294131 0.919
Run 1 Rep 2 678833 2.097 225362 3.916 124799 3.17 331195 0.914
Run 1 Rep 3 598566 2.1 223510 3.915 99313 3.177 638121 0.919
Run 2 Rep 1 557183 2.093 168469 3.917 79060 3.164 177270 0.917
Run 2 Rep 2 576977 2.094 196504 3.917 80991 3.168 189851 0.911
Run 2 Rep 3 565880 2.094 206488 3.916 96627 3.167 186016 0.912
Run 3 Rep 1 646750 2.093 208787 3.916 120868 3.17 261943 0.927
Run 3 Rep 2 611435 2.091 179931 3.911 95758 3.165 370705 0.92
Run 3 Rep 3 585398 2.098 191436 3.916 77283 3.172 346814 0.923
Std Dev. 39106 0.003 18722 0.002 17124 0.003 142800 0.005
Average 603095 2 199763 3.92 97480 3 310671 0.918
%RSD 6 0.143 9 0.046 17 0.124 45 0.563
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Run 1 Rep 1 125652 3.606 1752485 2.393 104761 1.064 185656 3.383
Run 1 Rep 2 131185 3.607 1983516 2.396 94308 1.065 153341 3.383
Run 1 Rep 3 132321 3.604 1832331 2.4 81256 1.073 208136 3.382
Run 2 Rep 1 104350 3.607 1743501 2.392 87683 1.064 147397 3.385
Run 2 Rep 2 122292 3.608 1900068 2.394 85423 1.057 169934 3.385
Run 2 Rep 3 118800 3.607 2018435 2.394 71131 1.071 151198 3.384
Run 3 Rep 1 116687 3.606 1962393 2.392 98537 1.069 195799 3.383
Run 3 Rep 2 108241 3.6 1973993 2.39 94875 1.065 124027 3.377
Run 3 Rep 3 115350 3.606 1828037 2.397 73082 1.075 152356 3.384
Std Dev. 9542 0.002 103168 0.003 11392 0.005 26773 0.002
Average 119430 3 1888307 2 87895 1 165316 3
%RSD 7 0.066 5 0.126 12 0.519 16 0.071




















Run 1 Rep 1 102625 3.167 294131 0.919 1433974 1.064 4534225 1.762
Run 1 Rep 2 124799 3.17 331195 0.914 1524385 1.068 3926219 1.763
Run 1 Rep 3 99313 3.177 638121 0.919 1538813 1.077 4002079 1.761
Run 2 Rep 1 79060 3.164 177270 0.917 1060027 1.063 4175818 1.763
Run 2 Rep 2 80991 3.168 189851 0.911 994562 1.055 4615533 1.763
Run 2 Rep 3 96627 3.167 186016 0.912 866735 1.027 3998668 1.764
Run 3 Rep 1 120868 3.17 261943 0.927 1566964 1.071 4214730 1.761
Run 3 Rep 2 95758 3.165 370705 0.92 1308875 1.069 3253384 1.758
Run 3 Rep 3 77283 3.172 346814 0.923 1651904 1.08 3934324 1.764
Std Dev. 17124 0.003 142800 0.005 285564 0.015 396993 0.001
Average 97480 3 310671 0.918 1327359 1 4072776 1
%RSD 17 0.124 45 0.563 21 1 9 0.107
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Run 1 Rep 1 3113086 3.288 947157 1.019 479631 1.012 428771 0.791
Run 1 Rep 2 3832463 3.29 889449 1.022 607528 1.014 288760 0.791
Run 1 Rep 3 3300553 3.305 1737933 1.035 928229 1.027 701459 0.792
Run 2 Rep 1 2907997 3.285 644294 1.017 339156 1.01 241126 0.789
Run 2 Rep 2 3004234 3.289 483475 1.014 351931 1.007 160550 0.782
Run 2 Rep 3 2975974 3.288 472024 1.028 341210 1.017 193179 0.774
Run 3 Rep 1 3260571 3.29 1001933 1.026 611273 1.018 268288 0.811
Run 3 Rep 2 3331431 3.284 1266546 1.024 756390 1.017 425867 0.796
Run 3 Rep 3 2913377 3.293 794816 1.043 483914 1.033 270796 0.797
Std Dev. 294043 0.006 400033 0.009 202802 0.008 166307 0.01
Average 3182187 3 915291 1 544362 1 330977 0.791
%RSD 9 0.187 43 0.888 37 0.807 50 1




















Run 1 Rep 1 1105604 0.886 1168861 2.223 261869 3.43 320752 3.145
Run 1 Rep 2 1223611 0.882 1286657 2.226 274026 3.432 482582 3.06
Run 1 Rep 3 1237416 0.884 12287439 2.211 257462 3.43 376873 3.068
Run 2 Rep 1 869530 0.884 1095501 2.222 252821 3.431 310748 3.055
Run 2 Rep 2 1032647 0.877 1224708 2.224 258504 3.432 326927 3.057
Run 2 Rep 3 856153 0.878 1269455 2.224 267472 3.431 389051 3.057
Run 3 Rep 1 651409 0.896 1201221 2.223 254660 3.43 400369 3.061
Run 3 Rep 2 838718 0.886 1216701 2.221 178470 3.426 306869 3.055
Run 3 Rep 3 869959 0.888 1167922 2.227 224068 3.429 246956 3.061
Std Dev. 196760 0.005 3694960 0.004 29416 0.001 68697 0.028
Average 965005 0.884 2435385 2 247705 3 351236 3
%RSD 20 0.637 151 0.208 11 0.053 19 0.94
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Run 1 Rep 1 320752 3.145 38269 0.997 1055295 1.938 884736 1.923
Run 1 Rep 2 317546 3.146 35962 1 1388283 1.941 1254017 1.925
Run 1 Rep 3 314006 3.144 29054 1.008 1678613 1.943 1330489 1.928
Run 2 Rep 1 295750 3.146 34637 0.997 709795 1.939 653941 1.924
Run 2 Rep 2 306862 3.147 36167 0.99 506625 1.941 503701 1.926
Run 2 Rep 3 302759 3.147 27518 1.006 548849 1.941 500784 1.926
Run 3 Rep 1 333191 3.145 34930 1.002 1082093 1.938 983577 1.923
Run 3 Rep 2 273978 3.14 36508 1 978869 1.936 930973 1.921
Run 3 Rep 3 271149 3.146 39828 1.012 1042576 1.942 906471 1.927
Std Dev. 20840 0.002 4023 0.006 379885 0.002 294384 0.002
Average 303999 3 34763 1 998999 1 883187 1
%RSD 6 0.068 11 0.66 38 0.116 33 0.115




















Run 1 Rep 1 476484 1.141 133521 4.315 295723 4.305 6120972 0.79
Run 1 Rep 2 476437 1.143 182057 4.315 431679 4.305 6395152 0.784
Run 1 Rep 3 473493 1.148 167363 4.313 385418 4.304 7118602 0.79
Run 2 Rep 1 284380 1.141 112228 4.315 274058 4.306 4500941 0.784
Run 2 Rep 2 255396 1.133 146611 4.315 387529 4.306 4856466 0.775
Run 2 Rep 3 162946 1.148 154287 4.315 418938 4.306 3900756 0.771
Run 3 Rep 1 441361 1.144 137493 4.314 373748 4.305 5223610 0.806
Run 3 Rep 2 574494 1.142 122882 4.1 320767 4.3 5243693 0.791
Run 3 Rep 3 148361 1.15 117438 4.315 318415 4.306 5903876 0.792
Std Dev. 155161 0.005 23360 0.071 55749 0.001 1004716 0.01
Average 365928 1 141542 4 356252 4 5473785 0.787
%RSD 42 0.445 16 1 15 0.044 18 1
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Run 1 Rep 1 1124179 3.711 2970320 1.439 1936537 1.835 1162355 1.7
Run 1 Rep 2 1298352 3.711 2912311 1.441 2249154 1.837 1208665 1.702
Run 1 Rep 3 1296265 3.71 3118931 1.441 2118852 1.84 1154086 1.703
Run 2 Rep 1 922972 3.711 2052569 1.439 2021507 1.835 1055524 1.7
Run 2 Rep 2 1043150 3.712 2175428 1.44 2115189 1.836 1145964 1.702
Run 2 Rep 3 1041672 3.711 2144107 1.442 2286934 1.837 1187418 1.701
Run 3 Rep 1 1271925 3.71 3014973 1.44 2243915 1.835 1300961 1.7
Run 3 Rep 2 1118305 3.705 3191591 1.437 2245110 1.833 1253091 1.698
Run 3 Rep 3 1060824 3.711 3326572 1.442 2129121 1.839 1217669 1.705
Std Dev. 131948 0.002 498693 0.001 117867 0.002 70200 0.002
Average 1130849 3 2767422 1 2149591 1 1187304 1






Run 1 Rep 1 1717392 1.372
Run 1 Rep 2 1529671 1.373
Run 1 Rep 3 1490835 1.373
Run 2 Rep 1 1602586 1.372
Run 2 Rep 2 1596522 1.372
Run 2 Rep 3 1653834 1.372
Run 3 Rep 1 175354 1.372
Run 3 Rep 2 1525477 1.369
Run 3 Rep 3 1559353 1.375
Std Dev. 474840 0.001
Average 1427891 1
%RSD 33 0.113
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Table 4: Summary of validation results
Parameter Acceptance Criteria: Results
Interference
Studies
No interfering signal from matrix, internal
standard, common drugs of abuse, OTC
drugs and prescription medication.
No observed interferences from
matrix or from common
drugs/metabolites
Carryover Carryover after a high concentration
sample must be less than 20% of the
mean decision point peak area.
No significant carryover observed at
20x the decision point concentration.
Limit of Detection The LOD is defined as the decision point.
Decision point concentrations are
attached as an appendix to this
document.





Less than 25% suppression or
enhancement and less than 15% CV due
to matrix (if not, evaluate impact on LOD)
Average suppression or
enhancement exceeded ±25% or the
% CV of the suppression or
enhancement exceeded 15 for
several drugs. The influence on
the above parameters were assessed
by evaluating the impact on the limit
of detection. Further assessment
demonstrated that there was no
impact on other critical validation
parameters.
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Table 5: Compounds with decision point concentrations
No. Drug Concentrationng/mL 2x 20x
1 Alprazolam 10 20 200
2 Amitriptyline 25 25 250
3 Amphetamine 10 20 200
4 Benzoylecgonine 50 100 1000
5 Caffeine 50-100
6 Carisoprodol 500 1000 10000
7 Chlordiazepoxide 50 100 1000
8 Clonazepam 10 20 200
9 Cocaine 10 20 200
10 Cyclobenzaprine 10 20 200
11 Dextromethorphan 20 40 400
12 Diazepam 20 40 400
13 Diphenhydramine 25 50 500
14 Estazolam 25 50 500
15 Ethylone 20 40 400
16 Flunitrazepam 10 20 200
17 Flurazepam 10 20 200
18 Lorazepam 10 20 200
19 MDMA 20 40 400
20 Meprobamate 500 1000 10000
21 Methadone 20 40 400
22 Methamphetamine 10 20 200
23 Methiopropamine 10 20 200
24 Methylone 20 40 400
25 Midazolam 50 100 1000
26 N-desmethyltramadol 20 40 400
27 Nordiazepam 20 40 400
28 Nortriptyline 25 50 500
29 Oxazepam 20 40 400
30 Phenazepam 25 50 500
31 Phencyclidine 10 20 200
32 Phentermine 20 40 400
33 Prazepam 10 20 200
34 Pseudoephedrine 100 200 2000
35 Tramadol 20 40 400
36 Trazodone 25 50 500
37 Zaleplon 10 20 200
38 Zolpidem 10 20 200
39 Zopiclone 50 100 1000
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VALIDATION PLAN
TOXICOLOGY UNIT // OSBI-FSC Laboratory
Scope: Drug Identification and Confirmation by LC/MS/MS
Matrix(ces): Blood
Analyte(s): See Attached List
Instrumentation: LC/MS/MS
Analytical Method(s): TX-34 addition




Carryover: Carryover after a high concentration sample must be less
than 20% of the mean decision point peak area.
Interference Studies: Evaluate interference from compounds currently in TX-39 as
well as other drugs commonly identified in the toxicology
laboratory.
Ionization Suppression/Enhancement: Less than 25% suppression or enhancement and < 15% CV
due to matrix (if not evaluate impact on LOD)
Limit of Detection: A minimum of three samples per run of a fortified matrix
sample at the concentration of the decision points shall be
analyzed over three runs to demonstrate that all detection
and identification criteria are met.  Decision point
concentrations attached as an appendix to this document.
Limit of Quantitation: N/A
Precision: N/A
Processed Sample Stability: N/A
Dilution Integrity (if applicable): N/A
Other Information: These compounds will be evaluated for the above indicated performance areas
according to the current Toxicology Quality Manual.
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Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has proven to be a powerful
tool for fast and reliable sample analysis in the OSBI toxicology lab.  Furthermore, it allows the
lab the flexibility to further refine and expand assay capabilities.
This document describes the validation for the identification and confirmation of many drugs that
screen positive by enzyme-linked immunosorbent assay. This validation demonstrates that the
procedure provides reliable results for the analysis of drugs identified and that meet the
acceptable criteria set for this application. The concentration range of target compounds used in
this validation was chosen to fit the recommended scope and cutoffs for identification and
confirmation as outlined in “Recommendations for Toxicological Investigation of Drug-Impaired
Driving and Motor Vehicle Fatalities”, Journal of Analytical Toxicology 2013;37:552–558.
Concentration ranges of target compounds not identified in this article were determined by
commonly encountered range of analyte concentrations seen in casework or literature review.
The sample preparation steps, as well as instrumental settings for use with blood matrices were
assimilated from the TX-34 method.  The validation parameters were assessed against the pre-
defined requirements listed in Table 1.
In brief, the procedure is outlined below:
 Pipet 100 µL blood to a microcentrifuge tube
 Pipet 100 µL 0.10 M Sodium Phosphate Buffer (pH=7.0) into microcentrifuge tube
 Add 500 µL of acetonitrile containing internal standards
 Vortex approximately 30 seconds
 Centrifuge at 13,200 rpm for 5 minutes
 Decant supernatant to conical tube
 Evaporate to dryness
 Reconstitute in 100 µL of reconstitution solvent and inject 20 µL.
Table 2: Validation parameters to be assessed
Parameter Acceptance Criteria:
Interference Studies Evaluate interference from compounds currently in TX-39 as well as
other drugs commonly identified in the toxicology laboratory.
Carryover Carryover after a high concentration sample must be less than 20% of
the mean decision point peak area.
Limit of Detection The LOD is defined as the decision point.  Decision point concentrations
are attached as an appendix to this document.
Ionization Suppression/
Enhancement
Less than 25% suppression or enhancement and <15% %CV due to
matrix (if not, evaluate impact on LOD)
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Interference Studies – Blank Matrices
Ten independent sources of blank whole blood were secured from previously analyzed cases
to evaluate matrix interferences. The blank matrix samples were extracted without the addition
of internal standard and analyzed using the method. No interferences for were detected.
Carryover
To evaluate carryover, high concentrations (20 times the target decision point concentration) of
blood fortified with the drug of interest were prepared and analyzed.  A blank sample was also
analyzed. The high concentration extract was analyzed with the instrument three times, each
immediately followed by analysis of the blank extract.  Analysis of the data showed that there
is no carryover of the high concentration sample into the following blank injections.
Ionization Suppression/Enhancement
The post-extraction addition approach was used to assess ionization
suppression/enhancement. Two different sets of samples are prepared and the analyte peak
areas of neat standards are compared to matrix samples fortified with neat standards after
extraction.
Set one consists of neat standards prepared at a high and low concentration for each
compound (20x and 2x the decision point). The neat standards were injected a minimum of six
times to establish a mean peak area for each concentration. Results of the two concentrations
are presented in Table 2.
Set two consists of ten different matrix sources. Each blank matrix sample was extracted in
duplicate. After the extraction was complete, each blank matrix sample was then fortified to
either the low or high concentration with each analyte. Each concentration set sample was
injected one time each.
The average area of each set was used to estimate the suppression/enhancement effect at
each concentration. The following equation was used to calculate the percentage of ionization
suppression or enhancement and % CV. Table 2 list the percentage of ionization suppression
or enhancement at each concentration for each analyte.
[1] ℎ (%) = − 1 100
[1] Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS, B. K.
Matuszewski, M. L. Constanzer, and, and C. M. Chavez-Eng, Anal. Chem. 2003 75 (13), 3019-3030.
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Table 2:  Ionization Enhancement/Suppression
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Pseudoephedrine Methiopropamine Methylone Codeine
Set 1 30981430 81943693 2515110 7278922 6559520 16499973 67991 136459.3




-66.17 -37.94 -68.97 -55.41 -56.77 -17.23 -48.91 11.48
% CV 6.69 5.43 7.39 6.25 5.54 3.96 6.98 7.95
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Amphetamine Oxycodone 6-MAM Methamphetamine
Set 1 3829846.8 12658331 138304.5 304673 40978.7 117496.2 6036401 23365532.2
Set 2 1709188.6 9638625 73788.3 315056.1 22313.2 116904.9 3602658 19326843.1
% Enhancement/
(Suppression) -55.37 -23.86 -46.65 3.41 -45.55 -0.50 -40.32 -17.28
% CV 9.08 4.81 14.48 7.78 15.47 7.93 8.20 4.20
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Ethylone Hydrocodone Phentermine MDMA
Set 1 6712424 17701944 301545.7 892789 4727226 15599319 7013868 22448939
Set 2 3992561 14800727 161303.7 777113.2 2950330 13614037 4029273 19223507
% Enhancement/
(Suppression) -40.52 -16.39 -46.51 -12.96 -37.59 -12.73 -42.55 -14.37
% CV 8.65 5.11 9.68 4.24 6.74 3.66 11.13 7.51
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Caffeine BE Tramadol n-Desmethyltramadol
Set 1 1088004 4635441 7775807 31491353 9843307 28074537 14775005 38325669
Set 2 2127731 4810856 6398559 29611702 7896898 27991314 10819447 37040026
% Enhancement/
(Suppression) 95.56 3.78 -17.71 -5.97 -19.77 0.30 -26.77 -3.35
% CV 58.73 14.29 10.74 3.68 6.22 3.14 8.20 1.42
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Cocaine Zolpidem Chlordiazepoxide Meprobamate
Set 1 5225668 10716941 3232078 10272182 3257821 10957646 33830417 50351760
Set 2 4061768 10131558 2505908 10343609 2399111 10289862 26350245 49256536
% Enhancement/
(Suppression) -22.27 -5.46 -22.47 0.70 -26.36 -6.09 -22.11 -2.18
% CV 3.96 5.30 6.77 5.52 7.01 6.53 5.12 1.23
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Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Trazodone PCP Dextromethorphan Diphenhydramine
Set 1 3263820 8784639 8634551 33902960 2484416 8816129 32825661 59586931
Set 2 2381710 8558473 7806750 34681210 1701682 8478124 25071822 52870382
[1] % EE/(Suppr) -27.03 -2.57 -9.59 2.30 -31.51 -3.83 -23.62 -11.27
% CV 4.01 4.92 7.24 4.70 6.58 4.73 8.17 1.48
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Midazolam Flurazepam Cyclobenzaprine Nortriptyline
Neat 2062941 7015459 1759836.7 5450462 1711863 6462559 2849405 102915277
Blank Matrix 1560127 7552946 1416259.2 5535664 915907 551829.6 1172152 8140935
[1] % EE/(Suppr) -24.37 7.66 -19.52 1.56 -46.50 -14.61 -58.86 -20.89
% CV 6.07 3.76 5.37 4.18 9.68 4.97 14.19 6.06
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Oxazepam Amitriptyline Methadone Clonazepam
Neat 1565073 19650617 474839.7 2217793 12797464 506951212 82896.3 584155.7
Blank Matrix 1389991 7757968 269894.2 1832978 10487914 51369991 114871.6 750418.9
[1] % EE/(Suppr) -11.19 -60.52 -43.16 -17.35 -18.05 1.33 38.57 28.46
% CV 5.13 3.83 11.24 4.50 6.05 4.72 6.83 3.88
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Carisoprodol Lorazepam Nordiazepam Alprazolam
Neat 34352234 63699639 342641.8 1722496 582987.7 2529640.5 114965.2 530138.5
Blank Matrix 288374423 62445260 291090.4 1678787 275299.7 1552872.3 131295.8 623905.8
[1] % EE/(Suppr) -16.05 -1.97 -15.12 -2.54 -52.78 -38.61 14.20 17.69
% CV 5.73 0.90 5.52 5.28 6.59 3.94 5.79 2.59
Average Peak Areas Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High Low High
Flunitrazepam Temazepam Diazepam Prazepam
Neat 435591.8 1721663 1226351.8 6324941 786458.8 2810601.5 1093593 4460037.5
Blank Matrix 312727.3 1628222 1134084.8 6242084 564253.2 2716065.5 578295 3920800.4
[1] % EE/(Suppr) -28.21 -5.43 -7.52 -1.31 -28.25 -3.36 -47.12 -12.09
% CV 6.70 3.74 11.17 5.22 5.83 2.83 9.11 4.41
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Average Peak Areas Average Peak Areas Average Peak Areas
Low High Low High Low High
Meth-d8 PCP-d5 Prazepam-d5
Neat 6979861.5 38678343 5675285 37880325 2925342 19262346
Blank Matrix 4211068 26757944 5484792 33939386 1611739 11261721
[2] % EE/(Suppr) -39.67 -30.82 -3.36 -10.40 -44.90 -41.54
% CV 6.06 5.19 2.57 3.52 6.64 7.11
2% Enhancement/Suppression
Limit of Detection
The method limit of detection (LOD) was evaluated using the cutoff for each analyte.  Three
separate analytical runs consisting of three replicates each were analyzed. In all samples, the
ion ratios were within 30% of the values set in the first sample of the LOD run and the retention
times of each compound has % RSD of less than one percent (Table 4).
Table 4: LOD Peak Area, Retention Times and Ion Ratios
6-MAM Alprazolam








Run 1 Rep 1 3529 1.06 48 14630 3.59 101
Run 1 Rep 2 3209 1.05 28 16407 3.59 102
Run 1 Rep 3 3046 1.05 64 15714 3.59 92
Run 2 Rep 1 2080 1.07 55 13368 3.62 124
Run 2 Rep 2 2848 1.08 53 14590 3.62 113
Run 2 Rep 3 3340 1.07 24 15707 3.61 89
Run 3 Rep 1 3497 1.09 39 14927 3.64 99
Run 3 Rep 2 2339 1.09 57 10865 3.65 91
Run 3 Rep 3 4258 1.05 22 11533 3.64 85
Std Dev. 654 0.016 16 1911 0.02 12
Average 3127 1.07 43 14193 3.62 100
%RSD 21 1.53 36 13 0.65 13
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Amitriptyline Amphetamine










Run 1 Rep 1 27008 3.21 82 50584 0.92 59 20
Run 1 Rep 2 34607 3.2 75 88638 0.92 36 21
Run 1 Rep 3 28290 3.27 79 80592 0.92 45 17
Run 2 Rep 1 27870 3.28 79 83820 0.93 44 20
Run 2 Rep 2 35768 3.27 75 250592 0.9 51 39
Run 2 Rep 3 36078 3.2 93 89950 0.93 41 18
Run 3 Rep 1 51048 3.28 82 118223 0.96 45 20
Run 3 Rep 2 48837 3.28 77 95249 0.96 43 21
Run 3 Rep 3 49042 3.28 70 87939 0.88 50 21
Std Dev. 9658 0.037 6 57291 0.03 7 7
Average 37616 3.25 79 105065 0.92 46 22
%RSD 26 1.14 8 55 2.76 14 30
Benzoylecgonine Carsioprodol








Run 1 Rep 1 665912 1.32 35 3827573 3.48 48
Run 1 Rep 2 721917 1.32 35 4246625 3.47 45
Run 1 Rep 3 656057 1.32 36 4101558 3.47 49
Run 2 Rep 1 642433 1.33 35 4357265 3.51 46
Run 2 Rep 2 694374 1.34 36 4419356 3.52 47
Run 2 Rep 3 604621 1.33 36 4214706 3.51 47
Run 3 Rep 1 681135 1.35 39 4584646 3.54 47
Run 3 Rep 2 552710 1.35 38 3873151 3.55 47
Run 3 Rep 3 504087 1.33 37 3632540 3.54 47
Std Dev. 70256 0.012 1 309781 0.03 1
Average 635916 1.33 36 4139713 3.51 47
%RSD 11 0.90 4 7 0.88 2
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Chlordiazepoxide Clonazepam








Run 1 Rep 1 197473 1.83 87 15837 3.29 30
Run 1 Rep 2 188391 1.82 84 13737 3.29 37
Run 1 Rep 3 201984 1.82 79 15076 3.29 25
Run 2 Rep 1 155511 1.86 84 10408 3.33 31
Run 2 Rep 2 164164 1.86 86 11592 3.34 40
Run 2 Rep 3 157858 1.85 87 12145 3.33 31
Run 3 Rep 1 203314 1.87 85 14875 3.36 28
Run 3 Rep 2 168472 1.88 83 13691 3.36 29
Run 3 Rep 3 171788 1.87 83 13971 3.35 38
Std Dev. 19138 0.02 2 1774 0.03 5
Average 178773 1.85 84 13481 3.33 32
%RSD 11 1.22 3 13 0.89 16
Cocaine Codeine










Run 1 Rep 1 260718 1.56 32 23 3310 0.89 33
Run 1 Rep 2 389636 1.56 30 21 3504 0.89 78
Run 1 Rep 3 363680 1.56 28 20 3158 0.88 92
Run 2 Rep 1 288106 1.58 35 25 3181 0.88 68
Run 2 Rep 2 299322 1.59 33 23
Run 2 Rep 3 362144 1.58 27 21 3507 0.9 36
Run 3 Rep 1 378525 1.59 29 20 3883 0.93 26
Run 3 Rep 2 319294 1.6 27 20 4852 0.92 35
Run 3 Rep 3 283237 1.59 30 22 5465 0.84 41
Std Dev. 47177 0.02 3 2 851 0.03 25
Average 327185 1.58 30 22 3858 0.89 51
%RSD 14 0.97 9 8 22 3.08 48
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Cyclobenzaprine Desmethyltramadol







Run 1 Rep 1 68273 3 48 896807 1.48
Run 1 Rep 2 73281 2.99 48 981378 1.48
Run 1 Rep 3 91307 2.99 45 945665 1.48
Run 2 Rep 1 75137 3.06 48 907799 1.5
Run 2 Rep 2 63623 3.07 52 921804 1.5
Run 2 Rep 3 59154 3.06 52 959393 1.5
Run 3 Rep 1 93207 3.06 47 870687 1.51
Run 3 Rep 2 73699 3.07 49 785738 1.52
Run 3 Rep 3 74484 3.07 49 753316 1.5
Std Dev. 11332 0.04 2 77093 0.01
Average 74685 3.04 49 891398 1.50
%RSD 15 1.19 5 9 0.94
Dextromethorphan Diazepam








Run 1 Rep 1 124025 2.13 100 58357 3.92 42
Run 1 Rep 2 151688 2.13 102 56421 3.92 46
Run 1 Rep 3 152283 2.13 103 58091 3.92 43
Run 2 Rep 1 146566 2.18 108 62591 3.93 43
Run 2 Rep 2 167380 2.19 98 62635 3.94 43
Run 2 Rep 3 159849 2.17 99 54754 3.93 43
Run 3 Rep 1 182580 2.19 99 20702 3.95 44
Run 3 Rep 2 161480 2.2 102 49994 3.95 42
Run 3 Rep 3 158040 2.2 101 45961 3.95 47
Std Dev. 15924 0.03 3 12989 0.01 2
Average 155987 2.17 101 52167 3.93 44
%RSD 10 1.41 3 25 0.34 4
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Run 1 Rep 1 742824 2.24 18 18 303573 1.04 57 37
Run 1 Rep 2 1665219 2.24 16 18 397864 1.04 57 33
Run 1 Rep 3 1492537 2.24 17 19 318744 1.04 60 37
Run 2 Rep 1 1969879 2.3 17 18 476331 1.06 60 34
Run 2 Rep 2 2084639 2.3 17 18 465316 1.07 62 35
Run 2 Rep 3 2004757 2.29 17 19 499943 1.05 64 37
Run 3 Rep 1 2311344 2.3 17 18 487087 1.07 59 36
Run 3 Rep 2 2075993 2.31 18 18 425452 1.08 61 38
Run 3 Rep 3 1954781 2.31 17 18 381825 1.03 65 39
Std Dev. 466713 0.03 1 0.4 72319 0.02 3 2
Average 1811330 2.28 17 18 417348 1.05 61 36
%RSD 26 1.38 4 2 17 1.64 5 5
Flunitrazepam Flurazepam








Run 1 Rep 1 30136 3.62 21 1555523 2.44 10
Run 1 Rep 2 34812 3.61 15 164083 2.43 10
Run 1 Rep 3 31474 3.61 18 154421 2.43 10
Run 2 Rep 1 26823 3.64 21 129404 2.49 11
Run 2 Rep 2 26366 3.65 21 134899 2.49 10
Run 2 Rep 3 26389 3.4 21 141233 2.48 10
Run 3 Rep 1 32708 3.66 21 147527 2.5 11
Run 3 Rep 2 27216 3.67 20 127444 2.52 10
Run 3 Rep 3 27240 3.66 18 127669 2.51 9
Std Dev. 3146 0.08 2 471733 0.03 1
Average 29240 3.61 20 298023 2.48 10
%RSD 11 2.30 11 158 1.40 6
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Hydrocodone Lorazepam








Run 1 Rep 1 15261 1.07 27 32272 3.41 45
Run 1 Rep 2 19368 1.07 27 32542 3.4 37
Run 1 Rep 3 13578 1.07 58 30276 3.4 45
Run 2 Rep 1 9537 1.09 28 22883 3.45 42
Run 2 Rep 2 17457 1.1 29 22106 3.45 50
Run 2 Rep 3 15455 1.08 48 26173 3.44 43
Run 3 Rep 1 16443 1.1 37 30107 3.47 48
Run 3 Rep 2 16313 1.1 29 29593 3.5 23
Run 3 Rep 3 14691 1.06 27 28877 3.49 45
Std Dev. 2741 0.02 11 3794 0.04 8
Average 15345 1.08 34 28314 3.45 42
%RSD 18 1.44 33 13 1.08 19
MDMA Meprobamate










Run 1 Rep 1 218948 1.07 57 34 4477001 1.78 77
Run 1 Rep 2 327444 1.08 55 33 4198461 1.78 79
Run 1 Rep 3 283122 1.07 51 35 4320051 1.78 76
Run 2 Rep 1 404347 1.09 53 33 3619824 1.8 76
Run 2 Rep 2 429329 1.1 49 33 3923987 1.81 75
Run 2 Rep 3 361803 1.09 51 35 4017818 1.8 79
Run 3 Rep 1 410641 1.1 53 33 4744052 1.83 75
Run 3 Rep 2 356436 1.1 55 35 3991218 1.83 76
Run 3 Rep 3 323026 1.06 53 34 3929247 1.82 78
Std Dev. 66945 0.02 2 1 337796 0.02 2
Average 346122 1.08 53 34 4135740 1.80 77
%RSD 19 1.39 5 3 8 1.14 2
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Methadone Methamphetamine










Run 1 Rep 1 518672 3.34 55 28 132676 1.03 31
Run 1 Rep 2 841482 3.34 56 27 220902 1.03 28
Run 1 Rep 3 754845 3.33 59 27 213055 1.03 30
Run 2 Rep 1 766868 3.42 57 29 289630 1.04 28
Run 2 Rep 2 698757 3.4 58 28 271284 1.05 32
Run 2 Rep 3 751781 3.39 59 29 275338 1.04 28
Run 3 Rep 1 869963 3.4 58 28 327762 1.06 29
Run 3 Rep 2 816983 3.41 58 28 294294 1.06 33
Run 3 Rep 3 792855 3.42 58 29 232083 1.01 29
Std Dev. 103140 0.04 1 1 58059 0.02 2
Average 756912 3.38 58 28 250780 1.04 30
%RSD 14 1.08 2 3 23 1.56 6
Methamphetamine-d8 Methiopropamine










Run 1 Rep 1 201185 1.02 47 36588 0.79 72 58
Run 1 Rep 2 293745 1.02 51 67386 0.78 76 52
Run 1 Rep 3 288043 1.02 42 73963 0.78 90 52
Run 2 Rep 1 390663 1.03 50 83797 0.78 96 66
Run 2 Rep 2 368044 1.04 49 96915 0.8 73 51
Run 2 Rep 3 372909 1.03 49 82970 0.79 93 63
Run 3 Rep 1 383104 1.05 50 79209 0.83 84 58
Run 3 Rep 2 418303 1.05 49 89536 0.82 78 47
Run 3 Rep 3 346553 1 48 85084 0.72 71 50
Std Dev. 67617 0.02 3 17464 0.03 10 6
Average 340283 1.03 48 77272 0.79 81 55
%RSD 20 1.57 5 23 3.95 12 12
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Methylone Midazolam










Run 1 Rep 1 172094 0.88 44 38 254006 2.26 22
Run 1 Rep 2 223776 0.88 46 45 251855 2.25 22
Run 1 Rep 3 277453 0.88 48 44 256457 2.25 21
Run 2 Rep 1 277453 0.88 48 44 241752 2.31 21
Run 2 Rep 2 250592 0.9 51 39 236564 2.31 21
Run 2 Rep 3 282617 0.89 49 43 235631 2.3 21
Run 3 Rep 1 312549 0.92 46 39 250879 2.31 22
Run 3 Rep 2 282705 0.92 43 42 235600 2.33 21
Run 3 Rep 3 232510 0.83 52 42 228261 2.32 21
Std Dev. 42120 0.03 3 3 10064 0.03 1
Average 256861 0.89 47 42 243445 2.29 21
%RSD 16 3.04 6 6 4 1.36 2
Nordiazepam Nortriptyline










Run 1 Rep 1 59139 3.4 46 78193 3.1 70 19
Run 1 Rep 2 47649 3.4 47 77061 3.1 70 20
Run 1 Rep 3 48840 3.4 53 96524 3.09 69 21
Run 2 Rep 1 43706 3.44 49 89800 3.17 70 17
Run 2 Rep 2 39128 3.44 43 67861 3.17 77 19
Run 2 Rep 3 45323 3.44 44 66851 3.16 70 21
Run 3 Rep 1 53473 3.47 47 124101 3.17 69 20
Run 3 Rep 2 48337 3.5 44 109068 3.18 66 21
Run 3 Rep 3 46727 3.49 45 92067 3.18 76 22
Std Dev. 5711 0.04 3 19034 0.04 3 1.5
Average 48036 3.44 46 89058 3.15 71 20
%RSD 12 1.11 7 21 1.21 5 7.5
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Oxazepam Oxycodone








Run 1 Rep 1 129110 3.17 70 5734 1.01 25
Run 1 Rep 2 127059 3.16 65 4412 1 37
Run 1 Rep 3 144164 3.16 60 5149 1.01 56
Run 2 Rep 1 86653 3.21 68 9290 1.01 20
Run 2 Rep 2 97192 3.22 66 8338 1.03 67
Run 2 Rep 3 94964 3.21 70 5275 1.01 29
Run 3 Rep 1 132365 3.23 63 6738 1.04 24
Run 3 Rep 2 118781 3.24 66 6400 1.03 24
Run 3 Rep 3 112180 3.23 72 5915 0.98 22
Std Dev. 19477 0.03 4 1568 0.02 17
Average 115830 3.20 67 6361 1.01 34
%RSD 17 0.99 6 25 1.78 49
PCP PCP-d5







Run 1 Rep 1 147756 1.97 61 130002 1.96
Run 1 Rep 2 419313 1.97 66 346284 1.95
Run 1 Rep 3 399331 1.97 73 368027 1.95
Run 2 Rep 1 525628 2.01 73 576361 2
Run 2 Rep 2 486626 2.02 73 517422 2
Run 2 Rep 3 573963 2.01 71 549486 1.99
Run 3 Rep 1 673210 2.02 65 629665 2.01
Run 3 Rep 2 557538 2.03 72 602137 2.02
Run 3 Rep 3 519111 2.03 73 530785 2.01
Std Dev. 148479 0.03 5 161162 0.03
Average 478053 2.00 70 472241 1.99
%RSD 31 1.30 6 34 1.37
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Phentermine Prazepam








Run 1 Rep 1 104165 1.15 18 49623 4.33 33
Run 1 Rep 2 160029 1.16 22 51729 4.32 33
Run 1 Rep 3 157513 1.15 23 53705 4.32 33
Run 2 Rep 1 138001 1.18 23 57419 4.33 32
Run 2 Rep 2 190449 1.18 17 45889 4.33 33
Run 2 Rep 3 193327 1.16 21 41722 4.32 31
Run 3 Rep 1 214905 1.18 22 60406 4.33 32
Run 3 Rep 2 201755 1.19 19 53219 4.34 32
Run 3 Rep 3 209156 1.15 20 50479 4.33 32
Std Dev. 37017 0.02 2 5633 0.01 1
Average 174367 1.17 21 51577 4.33 32
%RSD 21 1.36 11 11 0.15 2
Prazepam-d5 Pseudoephedrine










Run 1 Rep 1 256773 4.32 20 784885 0.78 25 21
Run 1 Rep 2 264322 4.31 20 962081 0.77 24 20
Run 1 Rep 3 288954 4.31 19 1046753 0.78 22 19
Run 2 Rep 1 329531 4.32 19 1460158 0.77 25 19
Run 2 Rep 2 256337 4.32 19 1599225 0.79 26 20
Run 2 Rep 3 222766 4.32 20 1325620 0.78 25 21
Run 3 Rep 1 302099 4.32 20 1354951 0.82 26 20
Run 3 Rep 2 284984 4.33 19 1185172 0.81 25 19
Run 3 Rep 3 271026 4.32 19 998203 0.71 24 20
Std Dev. 30701 0.01 1 264443 0.03 1 1
Average 275199 4.32 19 1190783 0.78 25 20
%RSD 1 0.14 3 22 3.98 5 4
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Temazepam Tramadol







Run 1 Rep 1 167112 3.73 40 603331 1.47
Run 1 Rep 2 162570 3.72 37 934143 1.46
Run 1 Rep 3 164941 3.72 41 846859 1.46
Run 2 Rep 1 118114 3.75 37 967566 1.49
Run 2 Rep 2 134665 3.75 37 975942 1.49
Run 2 Rep 3 129090 3.74 37 1013637 1.48
Run 3 Rep 1 159279 3.77 38 1024858 1.49
Run 3 Rep 2 154074 3.77 38 886884 1.5
Run 3 Rep 3 148360 3.77 39 887414 1.49
Std Dev. 17511 0.02 1 127957 0.01
Average 148689 3.75 38 904515 1.48
%RSD 12 0.55 4 14 0.98
Trazodone Zolpidem










Run 1 Rep 1 339845 1.86 97 43 237814 1.72 34
Run 1 Rep 2 356281 1.86 100 45 248504 1.72 36
Run 1 Rep 3 361254 1.86 99 48 237315 1.72 37
Run 2 Rep 1 355749 1.9 95 42 191778 1.75 39
Run 2 Rep 2 343545 1.91 86 45 217838 1.76 37
Run 2 Rep 3 338522 1.9 93 45 212096 1.75 38
Run 3 Rep 1 388189 1.91 92 44 254181 1.77 36
Run 3 Rep 2 319856 1.92 97 49 210161 1.78 36
Run 3 Rep 3 321335 1.92 96 46 209079 1.77 37
Std Dev. 21191 0.03 4 2 20948 0.02 1
Average 347175 1.89 95 45 224307 1.75 37
%RSD 6 1.37 4 5 9 1.35 4
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Table 5: Summary of Validation Results
Parameters: Desired Limit: Results
Interference Studies No interfering signal from matrix, internal standard, common
drugs of abuse (including other common opiates/metabolites),
OTC drugs, and prescription medications
No interferences
noted.
Carryover Carryover after a high concentration sample must be less than




Must be less than 25% and have a %CV of less than 15% at high
(20 times LOD) and low (2 times LOD) concentrations.  If these
values are exceeded, it must be demonstrated that there is no







Limit of Detection Target LOD concentrations are:
5 ng/mL – 6-acetylmorphine
10 ng/mL – alprazolam, amphetamine, clonazepam,




20 ng/mL – dextromethorphan, diazepam, ethylone,
MDMA,     methadone, methylone,  nordiazepam,
n-desmethyltramadol, oxazepam, phentermine,
temazepam, tramadol
25 ng/mL – amitriptyline, diphenhydramine,
notriptyline, trazodone
50 ng/mL – benzoylecgonine, caffeine,
chlordiazepoxide, midazolam, zopiclone
100 ng/mL – pseudoephedrine
125 ng/mL – carisoprodol, meprobamate
All target compounds
detected at the listed
concentrations.
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No. Drug Concentrationng/mL 2x 20x
1 Alprazolam 10 20 200
2 Amitriptyline 25 25 250
3 Amphetamine 10 20 200
4 Benzoylecgonine 50 100 1000
5 Caffeine 50-100
6 Carisoprodol 500 1000 10000
7 Chlordiazepoxide 50 100 1000
8 Clonazepam 10 20 200
9 Cocaine 10 20 200
10 Cyclobenzaprine 10 20 200
11 Dextromethorphan 20 40 400
12 Diazepam 20 40 400
13 Diphenhydramine 25 50 500
14 Estazolam 25 50 500
15 Ethylone 20 40 400
16 Flunitrazepam 10 20 200
17 Flurazepam 10 20 200
18 Lorazepam 10 20 200
19 MDMA 20 40 400
20 Meprobamate 500 1000 10000
21 Methadone 20 40 400
22 Methamphetamine 10 20 200
23 Methiopropamine 10 20 200
24 Methylone 20 40 400
25 Midazolam 50 100 1000
26 N-desmethyltramadol 20 40 400
27 Nordiazepam 20 40 400
28 Nortriptyline 25 50 500
29 Oxazepam 20 40 400
30 Phenazepam 25 50 500
31 Phencyclidine 10 20 200
32 Phentermine 20 40 400
33 Prazepam 10 20 200
34 Pseudoephedrine 100 200 2000
35 Tramadol 20 40 400
36 Trazodone 25 50 500
37 Zaleplon 10 20 200
38 Zolpidem 10 20 200
39 Zopiclone 50 100 1000
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In this procedure an extracting solvent is added to a sample, precipitating proteinaceous material.  
The sample is centrifuged and the supernatant is collected and evaporated to dryness.  The sample 
is then reconstituted and injected onto the LC/MS/MS for identification and confirmation. 
2. ASSOCIATED PROTOCOL(S) 
2.1 OSBI Laboratory’s Criminalistic Services Division Quality Manual 
2.2 OSBI Policy #121.1 OSBI Chemical Hygiene Plan 
3. SAMPLE(S) 
Preferred samples are fluoridated blood collected from outside agencies intended for human 
performance testing. 
4. REAGENTS 
4.1 Acetonitrile, LCMS reagent grade 
4.2 Methanol, LCMS reagent grade 
4.3 0.1% Formic Acid 
4.4 Bovine, synthetic or human drug-free blood 
5. SUPPLIES  
5.1 Disposable Microcentrifuge Tubes 
5.2 Five mL Disposable Conical Centrifuge Tubes with PTFE Lined Screw Caps 
5.3 Vortexer 
5.4 Disposable Pasteur Pipettes 
5.5 Eppendorf Pipettors - Fixed volume (10, 20, 25, 40, 50, 100, 200, 250 and 500µL) 
5.6 Eppendorf Pipettor - Variable volume (500-5000 µL) 
5.7 Nitrogen Evaporator 
5.8 Microcentrifuge 
5.9 Volumetric Flasks 
6. APPARATUS AND MATERIALS 
6.1 Liquid Chromatograph-Tandem Mass Spectrometer: Shimadzu LC-MS 8030 
6.2 Column: Phenomenex, Kinetex 2.6u C18 100A, Size 75 X 2.10 mm 
6.3 Nitrogen Generator 
6.4 Argon Supply 
7. SOLUTIONS  
7.1 Mobile Phase A (dH2O with 0.1% formic acid):  Add 4 mL of formic acid to 3.996 L 
dH2O.  Stored at room temperature up to 6 months. 
7.2 Mobile Phase B (ACN with 0.1% formic acid): Add 4 mL of formic acid to 3.996 L 
acetonitrile (ACN). Stored at room temperature up to 6 months. 
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7.3 Reconstitution solution, dH2O: ACN (9:1) with 0.1% formic acid: Add 5 mL of 
acetonitrile and 45 mL dH2O into a graduated cylinder and add 50µL of formic acid. 
Stored at room temperature up to one year. 
8. INTERNAL STANDARDS AND QUALITY CONTROLS 
Internal Standard 
8.1 Primary internal standards (100 µg/mL): Methamphetamine-d8 (ISTD), PCP-d5 (ISTD) 
and Prazepam-d5 (ISTD).   
8.2 Acetonitrile containing internal standards:  Add 200 µL of each deuterated primary 
internal standard to 250 mL of acetonitrile.  Store in the freezer for up to one year.  
Negative Control 
8.3 Negative Control: Add 250µL of drug-free whole blood in a microcentrifuge tube. 
Working Multi-Drug Control 
8.4 Primary standards (1.0 mg/mL): See Table 1 for CRM’s. 
8.5 Secondary working solution: Transfer volume of all non deuterated primary standard(s) 
listed in Table 1 into a 100 mL volumetric flask.  Dilute to the mark with dH2O.  
8.6 Tertiary working solution: Transfer 5 mL of secondary solution to a 10mL volumetric 
flask and dilute to the mark with dH2O. 
8.7 Working multi-drug control: Transfer 25 µL of tertiary working solution to 225 µL of 
drug-free whole blood in a microcentrifuge tube. 
Working Positive Control 
8.8 Primary standards (1.0 mg/mL): See Table 1 for CRM’s. 
8.9 Positive control secondary solution: Transfer volume of all primary standard listed in 
Table 1 into a 100 mL volumetric flask.  Dilute to the mark with dH2O.  
8.10 Positive control tertiary solution: Transfer 5 mL of positive control secondary solution 
to a 10mL volumetric flask.  Dilute to the mark with dH2O. 
8.11 Working positive control:  Transfer 50 µL of tertiary solution to 200 µL of drug-free 
whole blood in a microcentrifuge tube. 
9. INDIVIDUAL STEPS OF PROTOCOL 
9.1 Label clean disposable microcentrifuge tubes with controls and case sample IDs. 
9.2 Prepare the multi-drug, positive and negative controls (see Section “Solutions, Standards 
and Controls”).  Handle all controls in the same manner as case samples throughout 
extraction and analysis.   
9.3 Transfer approximately 250µL of each case specimen to the appropriately labeled 
microcentrifuge tubes.  
9.4 Add 500µL of cold acetonitrile (containing the internal standards) to each control and 
case specimen and vortex for approximately 30 seconds.  
9.5 Centrifuge all samples at 13,000 rpm for approximately 5 minutes. 
9.6 Transfer acetonitrile (top) layer to clean centrifuge tube. 
9.7 Evaporate to dryness at approximately 40°C with a steady stream of nitrogen. 
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9.8 Add 100µL of reconstitution solution and vortex briefly. 
9.9 Transfer sample to labeled autosampler vial and place into LCMS sample tray.  
9.10 Inject 20µL of sample into LC/MS/MS.  
9.11 Use the “TX-34.lcm” method for analysis. 
 
10. QUALITATIVE IDENTIFICATION 
10.1 The following are acceptable confirmatory practices in order of preference. At least one 
condition must be satisfied in order to identify and report a drug: 
10.1.1 Identification is made by the substance class and specific identification of the 
substance in an aliquot of sample by a different chemical principle (e.g., 
immunoassay followed by LC/MS/MS). 
10.1.2 Identification of the substance in one biological sample using two separate 
aliquots and one chemical principle (e.g., Clonazepam by LC/MS/MS). 
10.2 Qualitative Chromatographic Criteria 
10.2.1 The presence of the target analyte in the sample is indicated if: 
10.2.1.1 The chromatographic peak shape is Gaussian. 
10.2.1.2 The MRMs (i.e., precursor and products) being monitored line-up within 
their given retention time windows. 
10.2.1.3 The area counts are equal to or greater than the area counts of the multi-
drug positive control. 
10.2.1.4 The ion ratios for the analyte in the sample, established by the multi-
drug positive control, do not differ by more than ± 30%. 
10.2.1.5 The retention time for the sample does not differ by more than ±2% of 
the multi-drug control. 
11. QUALITY ASSURANCE REQUIREMENTS 
11.1 The multi-drug, positive and negative control will be injected immediately prior to 
casework. 
11.2 The relative ion ratios will be set for each day of analysis using the multi-drug control 
analyzed in each batch. 
11.3 The negative control must be free of any drugs except internal standards.  If not, re-
inject or re-extract. 
11.4 The positive and multi-drug control must be prepared from separate secondary control 
solutions. 
11.5 The positive control areas must be greater than the cut-off peak areas. 
11.6 If any problems cannot be remedied, stop casework and notify the technical manager. 
11.7  The LCMS method associated with this protocol is TX-34.lcm.  The TX-34.lcm method 
is found in the validation documents. 
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12. ANALYSIS DOCUMENTATION 
A packet containing original data for all controls and standards will be prepared for each analysis 
run and stored with the batch on the BEAST. 
13. RECOMMENDED REPORT WORDING 
13.1 The result of the examination will be reported as in the following examples:  
13.1.1 Results detected below the cut-off will be reported as “No drug(s) detected by 
LC/MS/MS.” 
13.1.2 A specimen is positive when its confirmatory drug test is equal to or greater than 
the cutoff.  Positive results will be reported as “The following drug(s) were 
confirmed by LC/MS/MS: [drug name].” 
14. ATTACHMENTS 
 Table 1: Analytical data for each of the 44 compounds in the LC/MS/MS database. 
15. REFERENCES 
15.1 Applications of LC-MS in Toxicology, ed. Aldo Polettini, (2006).    
15.2 Analysis of Benzodiazepines in Blood by LC/MS/MS, Agilent Technologies, (2006).  
15.3 The Mass Spectrometry Primer, Michael P. Balough, (2009). 
16. APPROVAL 
FTU Technical Manager  Date: ______________ 
 Matthew Stillwell   
 
   
Assistant Director  Date: ______________ 
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Product ion  
(Q2) 
µL of 1° Std to 
Make 100 mL of 2° 
Standard 
6-Acetylmorphine 328.1 165 211.2  10 
Alprazolam 309 281 205  20 
Amitriptyline 278.4 105 233.05  50 
Amphetamine 136.2 91.1 65.1 119.1 20 
Benzoylecgonine 290 168 105  100 
Caffeine 195 138 42 110 100 
Carisoprodol 261 97.1 158.2  250 
Chlordiazepoxide 299.9 227.1 283.15  100 
Clonazepam 316 270 214  20 
Cocaine 304 182.05 81.95 105.1 20 
Codeine 300.1 165.15 198.8  20 
Cyclobenzaprine 276.05 215.1 84.1  20 
Dextromethorphan 272.15 147.05 171.05  40 
Diazepam 285 154 193  40 
Diphenhydramine 256 167.1 165.1 152.1 50 
Ethylone 222.2 173.95 204 146 40 
Flunitrazepam 314 268 239  20 
Flurazepam 387.9 315 288  20 
Hydrocodone 300.1 198.85 171  20 
Lorazepam 321 275 229  20 
MDMA 194 163.1 105.15 77.1 40 
Meprobamate 219.1 158.15 97.15  250 
Methadone 310.2 265.15 105 57.1 40 
Methamphetamine 150.2 91.1 119.1  20 
Methamphetamine-d8 (IS) 158 92.95 124   
Methiopropamine 156.2 96.95 58 125.1 20 
Methylone 208 160.05 208 132.05 40 
Midazolam 326 291 244  100 
N-Desmethyltramadol 250 44   40 
Nordiazepam 270.9 140 165  40 
Nortriptyline 264.15 233.05 91 218 50 
Oxazepam 287 241 269  40 
Oxycodone 316.1 212 174.9  20 
PCP-d5 (IS) 249.3 86.15    
Phencyclidine 244.2 86.2 91.15  20 
Phentermine 150.1 91 133.1  40 
Prazepam 325 271.05 140  20 
Prazepam-d5 (IS) 330 276 140   
Pseudoephedrine 166.1 148.05 91 132.95 200 
Temazepam 301.2 255 283  40 
Tramadol 264.3 58.15   40 
Trazodone 372.1 176.2 148.05 78.15 50 
Zolpidem 308 235 263  20 
Zopiclone 389.1 244.9 216.85 139 100 
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I.  Explanation of Request 
 
Name:   Date:  
 
Applies to (Policy/Procedure):  
  
Describe Requested Deviation:  
 
 



















Authorized/Rejected  (signature)  Date:  
III.  Quality Assurance Manager Authorization  
 
Acceptability Within General Quality Assurance Principles? YES/NO 




Authorized/Rejected  (signature)  Date:  
IV.  Criminalistics Division Director Authorization    
 
Authorized/Rejected  (signature)  Date:  
Effective Date:      
 
Deviations for Protocol TX-34 to be incorporated into the next revision:
8.5 Secondary Multi-drug standard: Transfer volumes of primary standards listed in Column B of
Table 1 to a 100 mL volumetric flask.  Dilute to the mark with water.
8.6 Tertiary multi-drug standard: Transfer 5.0 mL of the secondary multi-drug standard to a 10 mL
volumetric flask.  Add the volumes of primary standards listed in column C of Table 1 to the flask.  Dilute
to the mark with water.
8.7 Working multi-drug control:  Transfer 25 uL of tertiary multi-drug standard to 225 uL of drug-
free whole blood in a microcentrifuge tube.
8.9 Positive control secondary standard: Transfer volumes of primary standards listed in Column
D of Table 1 to a 10 mL volumetric flask.  Dilute to the mark with water.
8.10 Working positive control: Transfer 25 uL of positive control secondary standard to 225 uL of
drug-free whole blood in a microcentrifuge tube.
8.11 - Rescind
10.2.1.3 The ratio of analyte peak area to internal standard peak area for the sample is greater than
the same ratio in the multi-drug control.
10.2.1.4 The ion ratios for the analyte in the sample, established by the positive control, do not differ
by more than ±30%.
11.2 The relative ion ratios will be set using the positive control analyzed in each batch.
11.5 – rescind
Column A Column B Column C Column D Column E Column F
Compound








µL of 1° Std to
add to 5 mL of
2° Multi-Drug
Standard, then
dilute to 10 mL
total volume
µL of 1° Std to












10 50 5 50
Alprazolam 20 10 10 100
Amitriptyline 50 25 25 250
Amphetamine 20 10 10 100
Benzoylecgonine (100 ug/mL) 50 500 50 500
Caffeine 100 50 50 500
Carisoprodol 50 500 500 5000
Chlordiazepoxide 100 50 50 500
Clonazepam 20 10 10 100
Cocaine 20 10 10 100
Codeine 20 10 10 100
Cyclobenzaprine 20 10 10 100
Dextromethorphan 40 20 20 200
Diazepam 40 20 20 200
Diphenhydramine 50 25 25 250
Ethylone 40 20 20 200
Flunitrazepam 20 10 10 100
Flurazepam 20 10 10 100
Hydrocodone 20 10 10 100
Lorazepam 20 10 10 100
MDMA 40 20 20 200
Meprobamate 50 500 500 5000
Methadone 40 20 20 200
Methamphetamine 20 10 10 100
Meth-d8 (IS)
Methiopropamine 20 10 10 100
Methylone 40 20 20 200
Midazolam 100 50 50 500
N-Desmethyltramadol 40 20 20 200
Nordiazepam 40 20 20 200
Nortriptyline 50 25 25 250
Oxazepam 40 20 20 200
Oxycodone 20 10 10 100
PCP-d5 (IS)
Phencyclidine 20 10 10 100
Phentermine 40 20 20 200
Prazepam 20 10 10 100
Prazepam-d5 (IS)
Pseudoephedrine 200 100 100 1000
Temazepam 40 20 20 200
Tramadol 40 20 20 200
Trazodone 50 25 25 250
Zolpidem 20 10 10 100
Zopiclone 100 50 50 500
